CHI Podcasts

Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. For more information, please visit https://www.TriConference.com/Precision-Medicine

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field. For more information, please visit https://www.TriConference.com/Gene-Therapy

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI. Topics include: challenges in developing bioassays for cell & gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more For more information, please visit https://www.ImmunogenicitySummit.com/Workshop

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health. For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA. Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead. For more information, please visit https://www.LiquidBiopsySummit.com/Programs

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research. For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential. For more information, please visit https://www.TriConference.com/Digital-Pathology

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently. For more information, please visit https://www.TriConference.com/Precision-Medicine

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process. For more information, please visit https://www.triconference.com/Companion-Diagnostics

Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.

For decades, high-performance computing (HPC) has played a crucial role in advancing healthcare. Enabled by techniques like next-generation sequencing (NGS), modern computer systems have helped us understand the biology of disease and helped facilitate the development of newer more effective drugs. While once deployed mainly in research, today HPC is edging ever closer to front-line clinical care supporting advanced diagnostics, genetic counseling, and personalized medicine. While core bioinformatics applications aren’t going anywhere, modern medicine is increasingly a big data problem as well. Determining the optimal treatment depends on collaboration, the fusion of genetic data with other rich datasets like MRIs, ultrasound images, and population level studies. Increasingly analytics and AI techniques like machine learning are helping healthcare providers sift through massive amounts of data to make better decisions for patients more quickly and efficiently. For IT organizations, providing a foundation to support this rapid innovation has been challenging. With the need for increasingly specialized hardware, new application frameworks, cost challenges, and the need to share data as never before, institutions are increasingly embracing cloud computing. Univa has played a key role in helping life sciences companies manage diverse workloads on HPC clusters both on-premises and in the cloud. In this Podcast, Univa will discuss how workloads are evolving, share some of the pressures faced by their life-sciences customers, and discuss practical approaches to modernizing IT environments to support the increased variety of applications in the life sciences software ecosystem.

Dr. Bradley Perkins develops a digital platform that can estimate personalized ten year mortality risk. In this podcast, he shares with us what this platform is and how it works to protect and improve the health of individuals and families. In the era of personalized medicine, Dr. Perkins explains what the necessary steps to bring this platform to the general public, gives us other personalized medicine examples and how it will affect the cost of medical care. For more information, please visit http://www.TriConference.com/Precision-Medicine

A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic Medicine

A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans Affairs

A re-upload of a podcast with Marc Berger, M.D., Vice President, Real World Data & Analytics, Pfizer

Prof. Dai Fukumura gives a preview of his talk, shares some challenges of reprograming tumor microenvironment and what he would like to see more in this field. For more information, please visit http://www.DiscoveryOnTarget.com/Tumor-Myeloid-Cells/

Dr. Jeffrey Miller shares his experience in NK cell field in the last 20 years, comparing NK cells with T cells and their cost differences along with giving some advice to the young scientists in the field. For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/

Dr. James Trager shares a preview of his talk at the NK cell-based cancer immunotherapy meeting in Boston, discusses his next step in research and the vision of Nkarta in NK cell therapy development and what he’s looking forward to at this meeting such as the topics of inhibition of MIC protein shedding and NK cell metabolism. For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/

Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at PEGS Europe, 12-16 November 2018 in Lisbon, Portugal. For more information, please visit http://www.PEGSummitEurope.com/Optimising-Protein-Expression Topics Questions Include: Let's talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade? What potential solutions seem promising for some … challenges? Are there promising glimpses into using transient protein gene expression for clinical use today? You'll be discussing “Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What's the main theme you'd like to convey to your audience of protein engineers and researchers?

Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress. For more information, please visit http://www.BispecificAntibodyCongress.com/Bispecific-Antibody-Clinical-Relevance

Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California Dr. Jennifer Dien Bard shares her insights into what the biggest challenges and opportunities are in implementing molecular point-of-care testing for infectious disease diagnostics, and rapid genetic and phenotypic susceptibility testing. Jennifer will be speaking at Molecular Diagnostics for Infectious Disease and co-instructing a short course on Rapid Diagnostics for Antimicrobial Resistance at the Next Generation Dx Summit August 20 to 24, 2018 in Washington, DC. For more information please visit http://www.NextGenerationDX.com/Infectious-Disease-Diagnostics/ and http://www.NextGenerationDX.com/SC-6/

Prof. Massimo Cristofanilli shares his perspective on the future of liquid biopsy, the complementary purposes of CTC and cfDNA technologies, and when one should expect clinical utility of liquid biopsies. For more information, please visit http://www.NextGenerationDx.com/Circulating-Tumor-Cells/

Dr. Bruce Quinn talks about his latest work, challenges to implementing precision medicine, advice for overcoming them and tips for integrating into the clinic. He discusses exciting new developments that are emerging and where the field is heading. For more information, please visit http://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics/

Daryl Pritchard of PMC speaks to CHI on May 4th, 2018. Darryl will be speaking at a shared session between the Coverage and Reimbursement for Advanced Diagnostics Track and the Precision Medicine tracks at the upcoming Next-Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, D.C Topics include the chicken-or-the-egg conundrum of building evidence and gaining access, a study looking at the cost effectiveness of using NGS for clinical practice, challenges in the diagnostic reimbursement community and more. For more information, please visit http://www.NextGenerationDX.com/Reimbursement-Diagnostics/ and http://www.NextGenerationDX.com/Precision-Medicine/

Paul Yager of University of Washington speaks to CHI on May 4, 2018. Dr. Paul Yager from the University of Washington. Dr. Yager will be speaking at the Enabling Point-of-Care Diagnostics and the Microfluidics and Lab-on-a-Chip Devices for point-of-care testing tracks at the upcoming Next Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, DC. Topics include his lab’s success in developing NAAT testing, obstacles to developing low cost diagnostics and advice for those looking to get into the field. For more information, please visit http://www.NextGenerationDX.com/Point-of-Care-Diagnostics/ and http://www.NextGenerationDX.com/Microfluidics/

Suman Bose of Massachusetts Institute of Technology speaks to CHI on May 3, 2018. Dr. Bose will be speaking at the Single Cell Analysis and at the Microfluidics and Lab-on-a-Chip Devises for point of care testing tracks at the upcoming Next Generation Diagnostics Summit that is held from August 20th through the 24th in Washington, D.C. Topics include motivation for single cells analysis, overcoming challenges and outlooks for the Summit. For more information, please visit http://www.NextGenerationDX.com/Microfluidics/ and http://www.NextGenerationDX.com/Single-Cell-Analysis/

Dr. James Hendler of Rensselaer Polytechnic Institute speaks to Cambridge Healthtech Institute on April 13, 2018. He will be a presenter during the Machine Learning and Data Visualization & Exploration Tools tracks at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) What led you to work on precision wellness as a part of your research on artificial intelligence, agent-based computing, high-performance processing, and the Semantic Web (of which you’re one of the originators)? 2) Let’s discuss emerging technologies from machine learning and artificial intelligence. What applications do they have on healthcare? What’s their potential impact? 3) What role might AI-driven technologies have in enhancing data visualization in genomics, drug discovery, or clinical development? For more information, please visit http://www.Bio-ITWorldExpo.com/Data-Visualization/ and http://www.Bio-ITWorldExpo.com/Machine-Learning-Genomics/

Dr. Catherine Brownstein of Boston Children’s Hospital and Harvard Medical School speaks to Cambridge Healthtech Institute on April 10, 2018. She will be a presenter during the Clinical Genomics track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Let’s touch upon your gene discovery work. What determines the disease genes and conditions you study, with an eye on clinical impact? 2) How does research on rare and orphan disease enhance our understanding of medicine overall? 3) While you zoom in on rare diseases for the sake of broader knowledge, you also look broadly or globally to answer local questions, liaising between academia and industry, and partnering with clinicians with a shared goal of enhancing patient care. What do both the research and clinical sides need to contribute to the process, and what challenges still need to be ironed out? For more information, please visit http://www.bio-itworldexpo.com/clinical-omics/

Dr. Nirmala Shenoy of Rochester Institute of Technology speaks to Cambridge Healthtech Institute on April 6, 2018. She will be a presenter during the Data Transfer track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include: 1) Why have you focused your recent research on Internet architectures and protocols and computational challenges faced by network protocols? 2) Let’s address scalability. How will supporting high-speed data transfers in large or across multiple networks, or provisioning for larger amounts of high-speed data, impact the security of scientific data? 3) How have Internet and routing protocols evolved in the last decade, and what further changes do you foresee in coming years? For more information, please visit http://www.Bio-ITWorldExpo.com/Data-Transfer/

Tim Sweeney spoke to CHI to discuss his company’s work in using host response to diagnose and risk stratify patients with sepsis infections. He also discusses current shortcomings sepsis diagnostics, as well as what he sees as barriers in implementing rapid diagnostics and how the field is moving forward to overcome these barriers. For more information, please visit http://www.MolecularDXEurope.com/Infectious-Disease-Dx/

Dr. Choi-Fong Cho of Harvard Medical School spoke to CHI to discuss her breakthrough research and the development of BBB organoids to be used as a next-generation screening model for brain-penetrating molecules. She discusses next steps in her research, including investigating new compounds and drugs with this platform, as well as the potential to unlock new mechanisms and pathways. Dr. Cho is speaking at the Blood-Brain Barrier conference, part of World Preclinical Congress, taking place June 18-21, 2018 in Boston, MA. For more details, please visit: http://www.worldpreclinicalcongress.com

Dr. Andrew Bradbury talks about his latest work using NGS to build a single donor library, and shares lessons he has learned along the way. He describes the unique approach they are using at Specifica and outlines tips for creating antibody libraries with improved diversity and developability. For more information, please visit http://www.PEGSummit.com/Phage-Display/

Dr. Andreas Stange of TÜV SÜD talks about the practical impact of the new IVD regulation, how it will affect manufacturers and notified bodies, challenges in validation, and practical advice to prepare for these changes in companion diagnostics. For more information, please visit http://www.MolecularDXEurope.com/MDXE_Content.aspx?id=190671

Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward. For more information please visit http://www.MolecularDXEurope.com/Circulating-Tumour-Cells/

Dr. Jorg Tost recently spoke to CHI to discuss his work with the ice-COLD-PCR assay and how it is addressing current challenges in cfDNA analysis. He also discusses challenges related to data, new technologies, and including other biomarkers in addition to cfDNA for the most complete and accurate analysis. Dr. Tost is speaking at the Enabling Technologies for Cell-Free DNA Analysis conference, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal. For more information, please visit http://www.MolecularDXEurope.com/Cell-Free-DNA-Technology/

As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a study within 24 hours -- all of these scenarios are possible in the digital era of medicine. In this podcast, we will explore new methods for: · Integrating data from wearables, sensors, and apps into a study and constructing better measures of individual health · Developing novel endpoints based on an individual’s day-to-day experience · Leveraging big data and AI to predict disease onset, progression/regression, acute events, and identify key intervention points · Optimizing study recruitment and protocol compliance through digital channels For more information, please visit http://www.Bio-ITWorld.com

Cambridge Healthtech Institute’s Kent Simmons recently spoke with Dr. David Johnson, CEO of GigaGen, about his upcoming presentation “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods”, to be delivered in the Engineering Antibodies meeting at the 2018 PEGS Boston. PEGS is scheduled for April 30 - May 4, 2018 in Boston, with the antibodies program set for May 2-3. For more information, please visit http://www.PEGSummit.com/Engineering-Antibodies

Patrizia Paterlini-Brechot spoke to CHI to discuss her work in cell-based non-invasive prenatal diagnosis and some of the challenges in commercializing this technique. She also discusses the impact commercialized NIPD tests will have on the field of prenatal diagnosis and some of the new frontiers she expects will be next. Dr. Paterlini-Brechot is speaking at the Advances in prenatal Molecular Diagnostics meeting, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal For more information, please visit http://www.MolecularDXEurope.com/Prenatal-Dx/

Dr. David Barton summarizes the new EU IVD regulations and highlights their key features. He will explain what the ramifications of introducing these new regulations for labs and manufacturers will be and advice for people preparing for the change. For more information, please visit http://www.MolecularDXEurope.com/mdxe_content.aspx?id=190671

Steven Walfish of the USP recently spoke with CHI about his role in updating the USP Bioassay Chapters. He is currently leading the General Chapters Statistical Expert Committee. Steven also remarks on current challenges and how new technologies are changing the field of bioassays. To hear more, don’t miss his presentation in Optimizing Bioassays for Biologics at the PEGS Summit this May 3-4 in Boston, MA! For more information, please visit http://www.PEGSummit.com/Bioassays-Conference/

Dr. William Hallett outlines what he considers some of the greatest obstacles to assess immunogenicity of biologics. He also comments on the reason behind the new requirement for lower cut-point in assays, how to accelerate Biobetters to the market in the world of Biosimilars, and advice for the industry in biologic development to accelerate FDA approval. For more information, please visit http://www.PEGSummit.com/Immunogenicity/

An interview with the 2018 Young Scientist Keynote, Dr. Kipp Weiskopf. Insights into new exciting developments in the growing field of cancer immunotherapy, perspectives on where this field is heading, and trends shaping the next generation of cancer immunotherapy. For more details, please visit: http://www.PEGSummit.com/Plenary-Keynote/

Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of Clinical Trial Agreement Delays and How to Defeat Them. Débora is speaking at the Clinical Trial Forecasting, Budgeting and Contracting conference, part of SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. For more details, please visit: http://www.SCOPESummit.com

Dr. Wells, Professor of Pharmaceutical Chemistry at the University of California, San Francisco, shares insights about his upcoming and the keynote presentation in the Emerging Technologies for Antibody Discovery conference being held on January 11th and 12th at PepTalk. For more information, please visit http://www.CHI-PepTalk.com/Antibody-Discovery/

In this podcast from CHI on September 20, 2017, Stephen Carey speaks about Omniox’s quest to deliver oxygen into the tumor microenvironment to improve immunotherapy response. He also remarks on the challenges facing tumor microenvironment research and strategies to overcome them. To see him in person, check out the Targeting the Tumor Microenvironment conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Tumor-Microenvironment/

Real World Evidence (RWE) is today’s big data challenge in Life Sciences. Medical records, registries, consultation reports, insurance claims, pharmacy data, social media, and patient surveys all contain valuable insights that Life Sciences organizations need to ascertain and prove the safety, efficacy and value of their drugs and medical devices. Join us to learn from our expert panelists as they discuss how Pharmaceutical and Medical Device Manufacturers are accelerating the development of RWE with a metadata-driven, semantically-enriched approach that enables them to: • Unify, harmonize and ensure governance of information from diverse data sources • Transform data into evidence that proves product efficacy and safety • Identify data patterns, connections, and relationships for faster time to insight For more information please visit http://www.Bio-ITWorld.com

In this podcast from CHI on September, Vancheswaran Gopalakrishnan and Jennifer Wargo speak about their work at the MD Anderson Cancer Center to understand the role of the microbiome in melanoma therapies, and the challenges that microbiome researchers are facing as this emerging field continues to move forward. To see him in person, check out the Microboime in Cancer Immunotherapy conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Microbiome-Immunotherapy/

Dr. Neeta Vora of University of North Carolina Chapel Hill spoke to CHI to discuss new opportunities and challenges in fetal whole exome sequencing for prenatal diagnosis. She discusses technical challenges, issues surrounding patient counseling, the potential for performing exome sequencing on noninvasively obtained samples, and her current research. Dr. Vora is speaking at the Advances in Prenatal Molecular Diagnostics conference, taking place November 28-29, 2017 in Cambridge, MA. For details, visit: http://www.Healthtech.com/Prenatal-Diagnostics/

This podcast highlights the Plenary Keynote presentation that John Lambert will be giving at PEGS Europe, 13 November 2018 in Lisbon, Portugal. Dr. Lambert discusses the difficulties of bringing novel constructs to market; advice for people introducing new ADC products in the clinical setting; and some of the most exciting new developments and emerging applications for ADCs. He shares his thoughts on ADCs that target both cancer initiating cells and differentiated cancer cells and clinical results; escape mechanisms tumor cells use to avoid destruction by ADCs; how perception shifted over the last three –four years on ADCs; and how can ADCs be combined with immuno-oncology approaches.

Tauseef Butt, CEO of Progenra Inc. speaks to CHI on September 8, 2017. Dr. Butt will be presenting during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System, taking place this September 27-28 at Discovery on Target in Boston, MA. Topics include the benefits and challenges of immunomodulatory small molecules, Ubiquitin Protease (USP7) Inhibitors performance in animal models, Progenra’s discovery platform and their plans for developing other immunomodulatory strategies.

Dan Peer of Tel Aviv University speaks to CHI on September 8, 2017. Prof. Peer will be speaking during Emerging Oligonucleotide Therapeutics, taking place this September 27-28 at Discovery on Target in Boston, MA. Topics include how to deliver RNA molecules into specific target tissues, especially leukocytes, via systemic administration, working with RNA, CRISPR-based gene editing and clinical applications for Lipid-Based Nanoparticles and Extracellular Vesicles.

CHI interviews Dr. Craig Crews, Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University. Dr. Crews tells the story of the birth and evolution of PROTACs, provides commentary on preclinical challenges, and provides his outlook for continued development. Discussion and Questions Include: • The ability to target components of the Ubiquitin Proteasome System with bifunctional PROTACs molecules has recently generated significant interest within the drug discovery community. Can you share with us a bit about the history and progression of this new mode of drug action? • There are several commercial entities currently working on a new generation of bifunctional molecules, including Arvinas, a biotech you’ve founded. Can you discuss some of the current challenges surrounding this approach during pre-clinical development? • You are chairing a session and giving a keynote address during the upcoming Targeting the Ubiquitin Proteasome System conference, September 26-27 in Boston. Can you share with us a bit on what you hope to convey during the session and keynote lecture? • We would like your opinion on the future of PROTACs – which appears to be very promising. We’ve talked about some of the current challenges, but can you share with us how you are working to address and overcome these challenges for continued development? For more information, please visit http://www.DiscoveryOnTarget.com/Ubiquitin-Proteasome/

Avni Santani of CHOP speaks to CHI on Tuesday August 1st, 2018. Dr. Santani will be speaking during the Clinical NGS Assays: Applications and Interpretation meeting at the Next Generation Diangostics SummitAugust 15-18, in Washington DC. Topics include using a CHOP strategies for integrating NGS into clinical care, what challenges they have run into and new applications of NGS For more information, please visit http://www.NextGenerationDx.com/ngs-diagnostics

Danny Wells speaks to CHI on July 6th, 2017. Dr. Wells will be speaking during Neoantigen-Based Personalized Immunotherapies meeting at ImPACT: Immunotherapy Progress and Clinical Treatments, December 5-7th, 2018 in San Diego, California. Topics include scaling up personalized therapies, future clinical applications of neoantigens, and new frontiers in cancer immunotherapy. For more information, please visit http://www.ImpactImmunotherapy.com/Neoantigen-Immunotherapy/

Kerry R. Wiles of Vanderbilt University speaks to Cambridge Healthtech Institute on July 11, 2017. Her institution will be co-hosting and she herself will be a presenter and short course instructor during the Leaders in Biobanking Congress, October 25-27 in Nashville, Tennessee. Topics Include: Building the Cooperative Human Tissue Network with Lean Six Sigma principles to improve processes, how shifts in clinical care and surgical care affect biorepositories and scientists, and what it takes to sustain a biobank. For more information, please visit http://BiobankingCongress.com/Agenda#Day3 and http://BiobankingCongress.com/Short-Courses

Sarah Gray of the American Association of Tissue Banks speaks to Cambridge Healthtech Institute on July 7, 2017. She will be a presenter and short course instructor during the Leaders in Biobanking Congress, October 25-27 in Nashville, Tennessee. Topics Include: Expectations about the process of donating post-mortem tissue for biospecimen research, possible process improvements to better serve patients, and connecting researchers with donor families to build biobank credibility and enable public support of biospecimen donation for biomedical research. For more information, please visit http://www.BiobankingCongress.com/Agenda/ and http://www.BiobankingCongress.com/Short-Courses/

Dr. Elena Grigorenko of Diatherix, speaks to CHI on Wed. July 19, 2017. Dr. Grigorenko will be speaking during the Molecular Diagnostics for Infectious Disease Conference August 16-17, 2017 at the Grand Hyatt Washington in Washington, DC

Dr. Allen Northrup from MIODx recently spoke with CHI about the future applications of point-of-care in treating cancer. He will be speaking at the Next-Generation Dx Summit in the Enabling Point-of-Care Diagnostics conference on August 15. He is working on developments to predict and monitor patients’ responses to immunotherapy. For more information, please visit http://www.NextGenerationDx.com/Point-of-Care-Diagnostics/

Andrew Ko from UCSF recently spoke with CHI about his collaboration with Two Pore Guys, and the innovations they are implementing using point-of-care devices in liquid biopsy. He will be speaking at the Next-Generation Dx Summit in the Enabling Point-of-Care Diagnostics conference on August 15. Dr. Ko is working with Two Pore Guys advancing technology to enable cancer patients to monitor their progress from home. For more information, please visit http://www.NextGenerationDx.com/Point-of-Care-Diagnostics/

Michael Messenger and Alison Smith from the University of Leeds recently sat down with CHI to discuss their poster “Early cost effectiveness and value of information analysis to accelerate diagnostic test research and development - a case study in acute kidney injury” which won the Symposia Poster Award at the Molecular Medicine Tri Conference this year. They describe their process of developing new diagnostic tests which considers both clinical utility and economic cost effectiveness. They also speak about what drew them to the Tri Conference this year and the connections that they were able to make with potential partnering companies. For more information, please visit http://http://www.TriConference.com/Student-Fellowship/

Travis Schlappi from the California Institute of Technology recently sat down with CHI to discuss his poster “Featured Poster: 30 Minute Phenotypic Antibiotic Susceptibility Test Directly from Clinical Samples” which won the Diagnostics World Early Innovator Award at the Molecular Medicine Tri Conference this year. For more information, please visit http://www.TriConference.com/Student-Fellowship/

Georgios Kitsios of the University of Pittsburgh Medical Center spoke to CHI to discuss his latest research in rapid microbiome-based diagnostics of infectious disease and how he sees the microbiome filling a need in point-of-care diagnostics for infectious disease. He also discusses the epidemic of antibiotic resistance and how this has shaped his research in the critical care space, as well as the biggest challenges he and other scientists face in this field. Dr. Kitsios is speaking in the Advances in Microbiome Diagnostics symposium, taking place August 18, 2017 in DC as part of the Next Generation Dx Summit. For details, visit: http://www.NextGenerationDx.com/Microbiome-Diagnostics/

Cassandra Calloway of Children’s Hospital Oakland Research Institute and the Universities of California at Davis and San Francisco spoke to CHI to discuss how next generation sequencing, or massively parallel sequencing, is different from current methods used in DNA forensics. She discusses the benefits of this new technology and its potential for benefitting all forensics labs. Cassandra is speaking at NGS for DNA Forensics, taking place August 18, 2017 in DC as part of the Next Generation Dx Summit. For details, visit: http://www.NextGenerationDx.com

Charles River offers early discovery phase efficacy testing for novel therapies aimed at neurological and psychiatric conditions. Using a full range of different animal models, we use translational methods including in vitro assays, behavioral and cognitive testing and imaging to accelerate the development of novel CNS and neurological disease related therapies. Multi-modal study designs are essential for robust preclinical data that translate to success in the clinic. For more information, please visit http://www.WorldPreClinicalCongress.com/Translational-Strategies-CNS/

Robert Anders of Johns Hopkins Medicine speaks to CHI on May 16th, 2017. Dr. Anders will be speaking during the Biomarkers for Cancer Immunotherapy and Combinations meeting at the Next Generation Diagnostics Summit August 15-18th in Washington DC. Topics include the integration of genomic, proteomic and immunological markers for cancer immunotherapy, challenges in implementing multiplex approaches, and more. For more information, please visit http://www.NextGenerationDx.com/Biomarkers-Cancer-Immunotherapy/

Marc Williams of Geisinger Health System speaks to CHI on May 19th, 2017. Dr. Williams will be speaking during the Clinical NGS Assays: Applications and Interpretation meeting at the Next Generation Diagnostic Summit, August 15th to the 18th in Washington D.C. Topics include implementation of NGS in routine car, challenges to overcome and exciting applications of NGS. For more information, please visit http://www.NextGenerationDx.com/NGS-Diagnostics/

Jonathan Pan of Aevi Genomic Medicine speaks to CHI on May 15th, 2017. Dr. Pan will be speaking during the Companion Diagnostics: Strategy and Partnerships meeting at the Next Generation Diagnostic Summit, August 15th to the 18th in Washington D.C. Topics include precision medicine outside of oncology, unique genomic approaches, implementation in routine care and more. For more information, please visit http://www.NextGenerationDx.com/Companion-Diagnostics/

In this podcast from CHI on May 18th, Edana Holliday speaks about how Rx Clinic Pharmacy is working to integrate point-of-care testing and pharmacogenetic testing into their practice, and how use of these methods can bring doctors and pharmacists into new collaborations. To see her in person, check out the Pharmacy-Based Point-of-Care Testing conference, part of the Next Generation Diagnostics Summit, August 15-18th in Washington DC. For more information, please visit http://www.NextGenerationDx.com/Pharmacy-Diagnostics/

In this podcast from CHI, on May 11th, 2017 Liz Worthey, Faculty Investigator and Director at HudsonAlpha Institute for Biotechnology sat down to discuss her work in whole genome sequencing to diagnose and monitor rare diseases. She discusses her team’s work with standardizing NGS tests, utilizing sequencing as a diagnostic test, and challenges to making whole genome sequencing standard of care in clinical practice. To learn more, please visit http://www.NextGenerationDx.com/NGS-Based-Assays/

Omar Perez of Pfizer speaks to CHI on May 10, 2017. Dr. March will be speaking during the Companion Diagnostics: Strategy & Partnerships meeting at the Next Generation Diagnostics Summit, August 15-18th in Washington DC. Topics include using key commercialization challenges for precision medicine or companion diagnostics, starting the discussion between a diagnostic and a pharmaceutical company regarding co-commercialization and more. For more information, please visit http://www.NextGenerationDx.com/Companion-Diagnostics/

Keynote speaker Suzanne Belinson of Blue Cross Blue Shield Association speaks to CHI on May 9, 2017. Dr. Belinson will be speaking during the Coverage and Reimbursement of Advanced Diagnostics meeting at the Next Generation Diagnostics Summit, August 15-18th in Washington DC. Topics include using web-based platform where stakeholders can view evidence, if we need more standardized requirements for payers and regulators, and hopes for the conference. For more information please visit http://www.NextGenerationDx.com/Reimbursement-Diagnostics/

Cambridge Healthtech Institute interviews Dr. James Hickman, Professor of Nanoscience Technology, Chemistry, Biomolecular Science, and Electrical Engineering at the University of Central Florida regarding developing next-generation human body-on-a-chip systems to impact early drug discovery and basic research. For more information, please visit http://www.WorldPreclinicalCongress.com/Drug-Toxicity/ and http://www.WorldPreclinicalCongress.com/Disease-Modeling/

Alexis Sauer-Budge of Fraunhofer CMI and Boston University speaks to CHI on May 9, 2017. Dr. Sauer-Budge will be speaking during the Sample Preparation Track at the Biodefense World Summit, June 26-29, 2017, in Alexandria, VA. Traditionally, bacterial pathogens have been identified using culture-based methods that can take several days to obtain results. This can lead to physicians making treatment decisions based on an incomplete diagnosis. To decrease diagnosis time, we are developing novel devices and methods for isolating, concentrating, and detecting dilute viable pathogens and coupling these with novel downstream detection modalities.

Dr. Jeffrey Miller outlines what he considers to be some of the greatest obstacles to developing BiKEs and the new class of molecules called TriKEs, describes his method and what is unique about his approach, details unexpected discoveries, shares advice for introducing novel antibody therapeutics in the clinical setting and talks about what he considers some of the most exciting new developments emerging for bispecific antibody killer engagers. For more information, please visit http://www.PEGSummit.com/Bispecific-Antibodies-For-Oncology/

Yu Jin Park of Severance Hospital speaks to CHI on March 23, 2017. Mr. Park was a Poster Winner at the Molecular Medicine Tri-conference that ran this past February, 2017. Topics include using next generation sequencing in a gene panel for Autistic Spectrum Disorder(ASD). For more information, please visit http://www.NextGenerationDX.com/

Aidan Synnott of Charles River Laboratories speaks to CHI on May 3, 2017. Charles River Laboratories will be speaking during the Preclinical Models and Tools in Oncology - Part 1 and Tumor Models for Cancer Immunotherapy - Part 2, June 13-15,2017 in Boston, MA. Topics include overcoming challenges for cancer therapeutics, CAR-T cells, combination therapies and advice for drug companies looking to work with CROs For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Models/ and http://www.WorldPreclinicalCongress.com/Tumor-Models-Immunotherapy/

CHI interviews Dr. Christoph Pittius, Vice President and Head of Transactions, Global Portfolio & Product Strategy, Business Development at AstraZeneca AB about current challenges and future trends of biopharma alliances. Discussion points and questions include: 1) How are biopharma alliances and deal-making evolving? What specific trends do you see developing? 2)What are some of the biggest challenges seen in deal-making today? What are critical steps necessary to overcome these challenges to maximize the value of strategic partnerships? 3) What is your outlook for the future of strategic partnerships and deal-making? 4)What types of partnerships do you think will increase over time? For more information, please visit http://www.Healthtech.com/AMS/

Kathleen Myers from AristaMD and Denise Gomez from North County Health Services recently sat down with CHI to discuss their upcoming presentations at Medical Informatics World. In this podcast they discuss the issues and challenges with current referral processes and how providers can leverage telehealth and eConsult platforms to improve communication and better patient care. For more information, please visit http://www.MedicalInformaticsWorld.com/Telehealth/

Mollie Shields-Uehling of SAFE-BioPharma Association and Tom Johnson of Exostar speak to Cambridge Healthtech Institute on March 23, 2017. Their organizations are represented by a co-presentation during the Data Security conference at Bio-IT World Conference & Expo, May 23-25 in Boston, Massachusetts. For more information, please visit http://www.Bio-ITWorldExpo.com/Data-Security/

Stuart S. Martin of University of Maryland School of Medicine speaks to Cambridge Healthtech Institute on March 17, 2017. He will be a presenter and short course instructor during The Liquid Biopsy Summit, June 21-23 in San Francisco, California. For more information, please visit http://www.LiquidBiopsySummit.com/

Dr. Edward Patz outlines what he considers some of the greatest obstacles to developing novel antibodies from single human B cells, how he recognized a novel and unexpected target in lung cancer, the current status of the first novel antibody he developed, advice for people introducing novel antibody therapeutics in the clinical setting and exciting new developments emerging for antibodies derived from single human B cells.

Genomics analyses have become much more affordable over the recent years. Creating a growth that makes the Life Science market projected to be worth 20 Billion US Dollars by 2020. In fact, research centers and hospitals specialized in the fields of Bio IT, Sequencing and other Life Sciences have acquired the latest technologies for their applications. As the demand for genomics analyses grows, these organizations are constantly creating new and more digital information. Therefore, IT managers are confronted with the impact of Big Data and must improve their IT infrastructure to respond to the needs of their workflows. Mr. Steven Rietveld, of NODEUM, will introduce this market and its related challenges during this podcast.

Scott Hopes and John Chuang recently sat down with CHI to discuss their upcoming presentation at Medical Informatics World. They discuss reimbursement issues and possible solutions to overcome regulatory hurdles to make telehealth a viable and affordable care option. For more information, please visit http://www.MedicalInformaticsWorld.com/Telehealth/

Mohammad F. Kiani of Temple University speaks to Cambridge Healthtech Institute on March 9, 2017. He will be a presenter during the 3D Cellular Models conference at World Preclinical Congress, June 12-16 in Boston, Massachusetts. For more information, please visit http://www.WorldPreclinicalCongress.com/3D-Cellular-Models/

A podcast interview with PEGS speaker David Weis of the University of Kansas. Dr. Weis is speaking in the Biophysical Analysis of Biotherapeutics meeting, where he will give a presentation on the topic “Hydrogen Exchange Mass Spectrometry in Formulation Development and Similarity Assessment”

Liz Worthey of HudsonAlpha Institute for Biotechnology speaks to Cambridge Healthtech Institute on March 9, 2017. She will be a featured presenter during a shared session for the Clinical Genomics and Data Security conferences at Bio-IT World Conference & Expo, May 23-25 in Boston, Massachusetts. For more information, please visit http://www.Bio-ITworldExpo.com/

Tom Lawler, Founder & Managing Partner, BaywynSolutions spoke to CHI to discuss the role of teamwork in outsourcing relationships for clinical trials and some of the tangible challenges, delays, and errors that can come from teams lacking a collaborative framework. He also discusses some metrics groups can use to measure their success in their outsourced relationships. Tom is speaking at Outsourcing for Clinical Trials, taking place April 25-26, 2017 in Boston as part of the Clinical Trial Innovation Summit. For details, visit: http://www.ClinicalTrialSummit.com/Clinical-Outsourcing/

Dr. Thomas Kleen outlines some of the challenges biomarker discovery, discusses his role in the STIC/FDA Immunotherapy Biomarkers Taskforce, and the focus of his work at Epiontis as the Executive Vice President of Immune Monitoring in this podcast for the Biomarkers for Immunotherapy conference at Molecular Diagnostics Europe Summit. To learn more, please visit http://www.MolecularDXEurope.com/Immunotherapy-Biomarkers/

Vatche Kalfayan, Senior Director, Clinical Operations, Pfizer spoke to CHI to discuss the lessons learned about outsourcing for clinical trials from his experience working in pharma and founding a CRO. He discusses the biggest challenges clinical trial professionals are facing in their outsourcing models and strategies, as well as some examples of how the field is changing and what he’s working on to drive some of that change. Vatche is speaking at Outsourcing for Clinical Trials, taking place April 25-26, 2017 in Boston as part of the Clinical Trial Innovation Summit. For details, visit: http://www.ClinicalTrialSummit.com

Biotherapeutic drugs such as monoclonal antibodies (mAbs) have the potential to induce immunogenicity; therefore, it is critical to perform an immunogenicity assessment to ensure drug efficacy and patient safety. In general, an immunogenicity assessment is performed in a multi-tiered approach: screening of anti-drug antibodies (ADA), confirmatory test, titer assessment, characterization of ADA for neutralizing drug activity and isotyping. The goal of our work is to develop multiplex approaches on various platforms including Meso Scale Discovery (MSD), Luminex and Delfia for ADA characterization. To learn more, please visit http://www.PEGSummit.com/Immunogenicity/

Mike Elliott, of Atrium Consulting, discusses the current problems and challenges facing IT. He talks about how IT needs to move into a more visible space in the future, and begin taking a more proactive rather than reactive stance. For more information, please visit http://www.Bio-ITWorldExpo.com

Peter Emtage from Cell Design Labs recently spoke with CHI. He will be speaking at PEGS in the Preventing Toxicity in Immunotherapy conference on May 2nd, 2017. Cell Design Labs is working with small molecules to modulate CAR T cells, which would allow clinicians to monitor and prevent toxicity issues in cancer treatment. For more information, please visit http://www.PEGSummit.com/Immunotherapy/

Megan Allyse, Ph.D., Assistant Professor, Biomedical Ethics, The Mayo Clinic spoke to CHI to discuss the ethical implications that come with advancing NIPT technology, from informed consent and proper infrastructure to proper education for clinicians. She also speaks on how NIPT can serve the larger field of molecular diagnostics to understand what widespread translation looks like for precision medicine technologies. Dr. Allyse is speaking at the NIPT: What’s Next in Technology Development short course, taking place February 20, 2017 in San Francisco as part of the Molecular Med Tri-Conference. For details, visit http://www.TriConference.com/

Philip Arlen from Precision Biologics recently spoke with CHI. He will be speaking at PEGS in the Adoptive T Cell Therapy conference on May 3rd 2017. Precision Biologics is working with cancer vaccines to develop personalized cancer treatments that target tumors without damaging healthy human tissues. For more information, please visit http://www.PEGSummit.com/TCellTherapy/

Abhijit Patel of the Yale University School of Medicine recently spoke with CHI, on February 23, 2017 he will be speaking during the Circulating Cell-Free DNA Symposium at Molecular Medicine Tri-Conference. As a physician-scientist, Dr. Patel maintains an active clinical radiation oncology practice. His research group at Yale is working to develop and clinically validate novel noninvasive DNA- and RNA-based cancer diagnostics. In this podcast, Dr. Patel spoke to CHI to discuss the emerging technologies and challenges in liquid biopsy including developing robust and sensitive assays to detect early stage disease. For more information, please visit http://www.TriConference.com/Circulating-DNA/

Kent Simmons of CHI speaks with Dr. Tim Whitehead, Assistant Professor of Chemical Engineering and Materials Science at Michigan State University About his upcoming keynote presentation “Programming Proteins by Deep Sequencing and Design” at PEGS Boston 2017. For more information, please visit http://www.PEGSummit.com/Immunogenicity-Mitigation/

G. Elisabeta Marai, Ph.D., Associate Professor, Electronic Visualization Lab, University of Illinois spoke to CHI to discuss her work in developing scalable systems for visual analysis on large-display environments, the inspiration behind the project, and how BactoGeNIE works today. She also discusses future challenges in displaying and visualizing large sets of bioinformatics data. Dr. Marai is speaking at the Data Visualization & Exploration Tools conference, taking place May 23-25, 2017 in Boston as part of the Bio-IT World Conference & Expo. For details, visit http://www.Bio-ITWorldExpo.com/Data-Visualization/

Dr. Kfir Oved outlines some of the greatest obstacles to controlling antibiotic misuse, advice for introducing new products in the clinical setting, describes some of the most exciting new developments emerging for AMR, and summarizes what he is looking forward to at the Advanced Diagnostics for Infectious Disease track at Molecular Diagnostics Europe Summit. For more information, please visit http://www.MolecularDXEurope.com/Infectious-Disease-Dx/

Dr. Bert Niesters discusses how standard practice in the emergency room setting has changed for both care delivered and spread of infection, the challenges associated with giving results rapidly and impact on the cost of care. He outlines improvements in their own system in emergency room care and plans for the future, and also talks about what he is looking forward to at the Point-of-Care Diagnostics track at Molecular Diagnostics Europe Summit. For more information, please visit http://www.MolecularDXEurope.com/Point-of-Care-Dx/

John Mattison of Kaiser Permanente speaks to CHI on November, 14, 2016. Dr. Mattison will be chairman at the Bioinformatics track during the Molecular Medicine Triconference, February 19 - 24, in San Francisco, CA. Topics include discussing the current state of bio-informatics and the large influx of information, as well as how to decide what information is pertinent with regards to which diseases. The talk concludes with his excitement to see how others are progressing along this topic as well. For more information, please visit http://www.TriConference.com/Bioinformatics-Big-Data/

Abhijit Patel of the Yale University School of Medicine recently spoke with CHI, on April 11, 2017 he will be speaking during the Cell-Free DNA in Clinical Oncology meeting at Molecular Diagnostics Europe. As a physician-scientist, Dr. Patel maintains an active clinical radiation oncology practice. His research group at Yale is working to develop and clinically validate novel noninvasive DNA- and RNA-based cancer diagnostics. In this podcast, Dr. Patel spoke to CHI to discuss the emerging technologies and challenges in liquid biopsy including developing robust and sensitive assays to detect early stage disease. For more information, please visit http://www.MolecularDXEurope.com/Clinical-Cell-Free-DNA/

Dexter Hadley of UCSF speaks to CHI on November, 29, 2016. Dr. Hadley will be speaking during the Bioinformatics track during the Molecular Medicine Triconference, February 19 - 24, in San Francisco, CA. Topics include developing a learning healthcare system to help make medicine more objective rather than subjective in terms of identifying melanoma and other symptoms, as well as creating an app to bring better personalized medicine to individuals. For more information, please visit http://www.TriConference.com/Bioinformatics-Big-Data/

Jaydev Thakkar of Amgen speaks to CHI on November 1st, 2016. Dr. Thakkar will be speaking during the Clinical Technology and Innovation conference at the SCOPE Summit, January 24-26, 2017 in Miami, FL. Topics include patient engagement from a data management perspective, using wearables to lower patient burden and tapping into novel endpoints. For more information, please visit http://www.SCOPESummit.com/Clinical-Data-Technology/

Brenda Yanak of Pfizer speaks to CHI on Oct 31, 2016. Dr. Yanak will be speaking during the Managing Precision Medicine Trials symposium at the SCOPE Summit, January 24-26, 2017 in Miami, FL. For more information, please visit http://www.SCOPESummit.com/

Diane Paskiet of West Pharmaceutical Services and Tilman Schlothauer of Roche speak to Cambridge Healthtech Institute. They are part of “It’s a Wrap”, the closing plenary panel discussion representing various R&D stages at PepTalk: The Protein Science Week, January 9-13 in San Diego, California. They each consider this question: What do you see as the next, most promising innovation in your field? For more details, please visit http://www.CHI-PepTalk.com/

Dr. Thomas Laue of University of New Hampshire, Bjørn Voldborg of Technical University of Denmark, and Dr. Andrew Fosberry of GlaxoSmithKline speak to Cambridge Healthtech Institute. They are part of “It’s a Wrap”, the closing plenary panel discussion representing various R&D stages at PepTalk: The Protein Science Week, January 9-13 in San Diego, California. They each consider this question: What do you see as the next, most promising innovation in your field?

CHI interviews Dr. Christopher Schofield, Head of Organic Chemistry in the Chemistry Research Laboratory at the University of Oxford, regarding his current work designing new demethylase inhibitors, current challenges, and his outlook for continued development in this space. Discussion Questions Include: How have you have seen this space evolve over the past few years? What are some demethylase targets currently being pursued by Medicinal Chemists? Can you please describe some of the work currently being conducted in your lab toward the discovery of new demethylase inhibitors? What challenges have been encountered designing small molecule histone demethylase inhibitors? How do you see this research evolving over the next few years? For more information, please visit http://www.DiscoveryOnTarget.com/Histone-Methyltransferases/

Bjørn Voldborg of Technical University of Denmark speaks to Cambridge Healthtech Institute on August 16, 2016. He will be a featured presenter at the Optimising Expression Platforms conference during PEGS Europe, 31 October - 4 November in Lisbon, Portugal. Topics include technological advancements in engineering CHO cell lines for increasing product yield and quality, challenges in recombinant protein expression over the last 20 years, and production of recombinant proteins as a science, not a service function.

Andrew Brooks of BioProcessing Solutions Alliance and Rutgers University speaks to Cambridge Healthtech Institute on August 3, 2016. Dr. Brooks will be presenting at the Leaders in Biobanking Congress, September 7-9 in Baltimore, Maryland. Topics include the evolution of biobanking quality control and standardization resources, goals and activities at Rutgers, challenges in biospecimen collection and storage for genomic research and clinical application, and harmonized biobanking to support precision medicine initiatives across multiple applications.

Anton Wellstein of Georgetown University Medical School speaks to Cambridge Healthtech Institute on August 1, 2016. He will be a presenter at the Leaders in Biobanking Congress, September 7-9 in Baltimore, MD. Topics include the importance of pre-analytical processing of samples, circulating nucleic acids in cancer treatment monitoring, and persistent challenges when linking cancer molecular markers with clinical information.

Susan Airhart of The Jackson Laboratory and Dr. Jens Rueter of Eastern Maine Medical Center speak to Cambridge Healthtech Institute on July 28, 2016. They will co-present a case study of their biobanker/R&D partnership at the Leaders in Biobanking Congress, September 7-9 in Baltimore, MD. Topics include the genesis and resources of The Jackson Laboratory’s PDX Consortium and the EMMC BioBank, their collaboration’s advancement of translational research, and how research with PDX models and biobank partnerships might evolve to contribute further to preclinical drug development and patient care. For more information, please visit http://www.HealthTech.com/Biobanking/Agenda#Day3

David Bick of HudsonAlpha speaks to CHI on July 20th, 2016. Dr. Bick will be speaking during the Health and Wellness Genomic Screening symposium at the Next Generation Diagnostics Summit, August 23-26th, in Washington DC. Topics include: Nik Volkner’s story of how genomic screening saved his life, the integration of genomic technologies into wellness programs and more. For more information, please vist http://www.NextGenerationDx.com/Health-Genomic-Screening/

Tim Minogue of the United States Army Medical Research Institute for Infectious Diseases speaks to CII on July 8, 2016. Tim Minogue will be speaking during the Molecular Diagnostics for Infectious Disease track at the Next Generation Diagnostics Summit, August 24th, in Washington DC. For more information, please visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics/

Dr. Ascierto will be discussing a historical perspective in treating melanoma and outline current clinical trials and real-world experience in immune checkpoint in melanoma, and detail what he considers some of the most exciting discoveries in the field. To learn more, please visit http://www.PEGSummitEurope.com/Cancer-Therapy/

Dr. Hatim Husain, Assistant Professor of Medicine in the department of Hematology and Oncology at UCSD spoke to CHI to discuss how using digital PCR has changed the way he conducts his research in oncology. He describes some of the benefits and challenges of integrating digital PCR into a laboratory, as well as discusses what he’s looking forward to seeing at the Digital PCR symposium. Dr. Husain will be speaking at the Digital PCR symposium taking place this August 26 at the Next Generation Dx Summit in Washington, DC. For details, please visit: http://www.NextGenerationDx.com/Digital-PCR/

Dr. Hinrich Abken will be discussing next generation CARs, comparison to other approaches, current efforts to improve on CAR molecules and advice for people in the field. For more information, please visit http://www.PEGSummitEurope.com/Phage-Display/

Jamie Platt of BRIDGenomics speaks to CHI on June 22, 2016. Dr. Platt will be speaking during the Health and Wellness Genomic Screening Symposium at the Next GenerationDiagnostics Summit, August 23-36, in Washington DC. Topics include next generation sequencing pricing, the challenges of implementing personalized medicine in the clinic and more. For more information, please visit http://www.NextGenerationDx.com/Health-Genomic-Screening

CHI interviewed Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies on the utilization of high-throughput sequencing and expert bioinformatics profiling T-cell and B-cell receptors, also known as immunosequencing, to enable the development of a new generation of cancer immunotherapies. Discussion questions include: 1. Can you tell us a bit about Adaptive Biotechnologies, its origins, and where you are as a company now? 2. Can you please tell us about immunosequencing, and its applications in preclinical and clinical settings? 3. You are giving a luncheon presentation during the Cancer Immunotherapy and Combinations meeting, June 15-16, 2016 in Boston. Can you give us an idea of what you hope to convey to attendees during this lecture? 4. What challenges exist that may be overcome in the near future? What does the future of Adaptive and immunosequencing look like? For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Immunotherapy-Combinations/

Chase Miller, Director of Research and Science, Eccles Department of Genetics, USTAR Center for Genetic Discovery, University of Utah School of Medicine spoke to CHI to discuss challenges in visualizing genomic data as well as how the IOBIO system helps address some of those challenges. He also discusses his favorite IOBIO application and what he’s looking forward to seeing at the conference. Dr. Miller is one of the developers of IOBIO and a speaker at the Data Visualization & Exploration Tools conference, taking place April 5-7 as part of the Bio-IT World Conference & Expo. For details, visit http://www.Bio-ITWorldExpo.com/Data-Visualization/

Dr. Jason Franasiak, Attending Physician at the Reproductive Medicine Associates of New Jersey, spoke to CHI to discuss the origins of germ theory and human microbiome research, specifically as it relates to human reproduction. He'll detail some of his research on the uteran microbiome during embryo implantation, future developments for diagnostics, and how other scientists may utilize his research and apply it to their own studies. Dr. Franasiak is one of our speakers for the Advances in Microbiome Diagnostics symposium, taking place August 26, 2016 in Washington, DC as part of the Next Generation Dx Summit. For details, visit www.NextGenerationDx.com/Microbiome-Diagnostics

Jeffrey Borenstein of Draper Laboratory speaks to Cambridge Healthtech Institute on May 9, 2016. Dr. Borenstein will present during the 3D Cellular Models meeting, part of the World Preclinical Congress, June 14-17 in Boston, Massachusetts. Topics include promising methods for recapitulating the in vivo microenvironment in 3D cell culture models, microfluidic technologies for multiplexed and interacting organ models, microsystems-based approaches for organ assist devices and organ models for drug efficacy and safety testing, and Draper Lab’s resources for that research. For more information, please visit http://www.WorldPreclinicalCongress.com/

Muneesh Tewari of the University of Michigan speaks to Cambridge Healthtech Institute on April 28, 2016. Dr. Tewari will give his keynote presentation during the conference program at The Liquid Biopsy Summit, June 22-24 in San Francisco, California. Topics include circulating extracellular RNAs as a liquid biopsy approach, developing novel biomarker methods that involve serial monitoring at high-time resolution, and researching circulating microRNA biomarkers for cancer and other diseases with a diverse scientific and medical background. For more information, please visit http://www.LiquidBiopsySummit.com/

Joerg Holenz of AstraZeneca previews his in-depth course on Modern Lead Generation Strategies and highlights the important issues on this subject. Joerg will be speaking during the Mastering Medicinal Chemistry meeting, June 15-16, in Boston, MA. For more information, please visit http://www.WorldPreclinicalCongress.com/

Dr. Robert D. Bell, Principal Scientist, Integrative Neuroscience at Pfizer spoke to CHI to discuss challenges in in researching the blood-brain barrier for creating effective treatments, as well as future directions and potential research avenues. He also discussed the topics and speakers he’s excited to see at the Blood-Brain Barrier conference this June. Dr. Bell is one of our chairpeople and roundtable moderators at the Blood-Brain Barrier conference, taking place June 15-16, 2016 in Boston, MA as part of the World Preclinical Congress. For details, visit http://www.WorldPreclinicalCongress.com/Blood-Brain-Barrier/

Victoria Mosolgo interviews Dr. Tom Laue of the University of The University of New Hampshire. Dr. Laue will be giving a keynote presentation in the High-Concentration Protein Formulations track at the 8th Annual Bioprocessing Summit taking place August 15-19, 2016 in Boston. To learn more, visit http://www.BioprocessingSummit.com/

Jamie Platt of BRIDGenomics, LLC speaks to Cambridge Healthtech Institute on April 21, 2016. Dr. Platt will give her presentation during the conference program at The Liquid Biopsy Summit, June 22-24 in San Francisco, California. Topics include changes in the landscape of development and commercialization of molecular diagnostics, issues and emerging opportunities for liquid biopsy sample prep, and process/technology refinements necessary for broader, routine application of liquid biopsies. For more information, please visit http://www.LiquidBiopsySummit.com/

Dr. Cory Abate-Shen of Columbia University Medical Center speaks to CHI on April 8th , 2016. Dr. Abate-Shen will be presenting during the Preclinical Models in Oncology conference at the 2016 World Preclinical Congress, June 14-17 in Boston, MA. For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Models/

CHI recently interviewed Jonathan Hughes, Partner and Practice Lead of Outsourcing and Supply Chain Management at Vantage Partners about the evolution of Sponsor-CRO strategic partnerships to date; challenges and opportunities in forming these types of partnerships; and an outlook on how these partnerships will continue to evolve. Discussion points and questions include: 1. Can you tell us a bit about yourself and the role you play at Vantage? 2. Forming strategic alliances with CROs has not traditionally been the route sponsors have taken. Why has this changed and where are we now? Also, how have sponsors and CROs adapted over the years? 3. What are some of the unforeseen risks and benefits of moving beyond a traditional customer-vendor relationship? 4. During the upcoming Strategic Alliance Management Congress Vantage will be hosting a luncheon workshop focused on managing sponsor-CRO partnerships. Can you give us any insights as to what attendees can expect to learn during this? 5. We like to end our podcasts with an outlook. In your opinion, how will Sponsor-CRO relationships continue to evolve? For more information, please visit http://www.HealthTech.com/AMS/

György Kosztolányi, Ph.D., President, Human Reproduction Committee of Scientific Health Council, Professor Emeritus, University of Pécs, Hungary spoke to CHI to discuss the ethical challenges of preimplantation testing as well the latest research and developments, including the potential for using extracellular DNA. He also raises questions on whether IVF babies, when they grow into adults, might view their genetic information and how we may handle this in the future. Dr. Kosztolányi is our moderator for the closing panel discussion at the Reproductive Genetic Diagnostics conference, taking place 6-7 April as part of the Molecular Diagnostics Europe event. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX/

Samantha A. Schrier Vergano of Children’s Hospital of the King’s Daughters speaks to Cambridge Healthtech Institute on February 15, 2016. Dr. Schrier Vergano will give her presentation during a shared session for the Clinical Genomics and Open Source Innovations conferences at Bio-IT World Conference & Expo, April 5-7 in Boston, Massachusetts. Topics include challenges when validating clinical utility of genetic variants, ethical quandaries of sharing genetic data in clinical settings and focusing on medical genetics with a pediatric angle. To learn more, please visit http://www.Bio-ITWorldExpo.com/

Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI. The topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.MolecularDXEurope.com/

CHI president Phillips Kuhl and Sequenom CMO Daniel Grosu discuss how Sequenom is applying new technology to address the next sets of clinical questions for non-invasive prenatal testing. To learn more, please visit http://www.MolecularDXEurope.com/

Louis Fiore of Veterans Affairs Boston Healthcare System speaks to Cambridge Healthtech Institute on February 10, 2016. Dr. Fiore will give his presentation during a shared session for the Clinical Genomics and Cancer Informatics conferences at Bio-IT World Conference & Expo, April 5-7 in Boston, Massachusetts. Topics include aggregating and reusing Electronic Health Record (EHR) data for quality improvement, discovery and validation of genomic knowledge; MAVERIC's Point of Care Research Program and Precision Oncology Program; the value of Veterans Affairs programs for clinical genomics research; and empowering clinicians to make more informed decisions for patients. To find out more, visit http://www.Bio-ITWorldExpo.com/

CHI recently interviewed Dr. Dmitry Samarsky, Senior Vice President of Technology and Global Business Development at OliX Pharmaceuticals, regarding the evolution of nucleic acid-based therapeutics; challenges within this space; recent advances in chemistry and delivery; and the greatest opportunities within this space over the next few years. Discussion questions include: 1 Given the obvious benefit of oligonucleotide therapies being able to dramatically expand target space, why haven’t they impacted the drug development landscape as much as Biologics or small Molecules? What challenges have been encountered within this field? 2 It seems as if there has be a resurgence of interest in the discovery and development of oligonucleotide therapeutics. Why do you think this is? What has changed over the past few years? 3 You are hosting a workshop during the upcoming Oligonucleotide Therapeutics and Delivery conference, providing an overview of oligonucleotide therapeutics from discovery to manufacturing. Can you tell us more about this workshop? Who should attend this? What can they expect to learn during this? 4 Oligonucleotide therapeutics seem to be evolving rapidly, but in your opinion, where do you see the greatest opportunities within this space over the next few years? For more information, visit http://www.HealthTech.com/Oligonucleotide/

Ralph Minter of MedImmune will describe his approach for phenotypic antibody screening and how it is being used to discover both novel antibodies and targets. He will discuss tips for overcoming obstacles to identifying novel targets, share advice for getting best results with phenotypic screening and describe how this work has been impacted by recent discoveries in the tumor microenvironment. For more information, please visit http://www.PEGSummit.com/

Romney Humphries, Assistant Professor, UCLA Pathology & Laboratory Medicine, Section Chief of Clinical Microbiology, David Geffen School of Medicine, University of California, Los Angeles spoke to CHI to discuss how Next-Generation Sequencing has changed the way scientists detect antimicrobial resistance as well as the challenges scienctists face moving forward. Dr. Humprhies is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the Molecular Medicine TriConference. For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/

CHI speaks with Dr. Klaus Pantel, a professor and founding director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf in Germany. In this podcast Dr. Pantel discusses the steps needed to make liquid biopsy the standard-of-care, its most promising applications, and future directions. Dr. Pantel also adds his voice to the debate over whether or not early detection is viable, and in which indications it may make the most sense. For more information, please visit http://www.MolecularDXEurope.com/

CHI chats with Dr. Raymond J. Langley, Assistant Professor, Department of Pharmacology, University of South Alabama. Dr. Langley discusses the latest research and developments in metabolomics risk analysis models for sepsis and predictive biomarkers for patient survival, as well as the current challenges in developing technology for metabolomics diagnostics for sepsis. Dr. Langley is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the . For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/

CHI chats with Bert Smeets, Ph.D., Professor, Clinical Genomics, Mitochondrial Diseases, Maastricht University Medical Center. Dr. Smeets discusses the latest research and developments on diagnosing mtDNA disease using Next-Generation Sequencing, as well as his work in developing techniques to prevent mtDNA disease transmission and developing therapeutics for those affected by mtDNA disease. Dr. Smeets is one of our speakers for the Novel Diagnostic Approaches session at the Reproductive Genetic Diagnostics conference, 6-7 April, in Lisbon. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX

Peter Luppa of the Technishe Universität in München will outline what he considers some of the greatest obstacles to implementing POC testing in the clinical setting and describe the need for quality standards. He will share advice for introducing POCT within the clinical setting and some of the most exciting applications emerging for POC and how they fit into the theranostic/health monitoring ecosystem.

Dr. Ian Hunt of Novartis speaks to CHI on December 1, 2015. Dr. Hunt will be presenting during the Applying Expression Platforms conference at 2016’s PepTalk, January 18-22 in San Diego, California. Topics include development of high-throughput protein technologies and different strategies to make more difficult proteins, the recent explosion in technologies to solve X-ray crystallography of GPCRs, applying such technologies into the drug discovery context, generation of very large protein complexes and more. Find more information at http://www.CHI-PepTalk.com/

Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30. Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18. Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.HealthTech.com/Prenatal-Diagnostics/

CHI chats with Rebekah S. Zimmerman, Ph.D., FACMG, Director, Clinical Genetics, Foundation for Embryonic Competence. Dr. Zimmerman discuss the latest technologies she and her non-profit lab are working with and developing, including how the non-profit lab is different from a typical PGD lab. Dr. Zimmerman is one of our speakers for the Advances in NGS and Other Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.Healthtech.com/Reproductive-Genetic-Diagnostics

Dr. Niall Barron of Dublin City University speaks to CHI on August 28, 2015. Dr. Barron will be presenting during the Engineering Expression Systems conference at the 2015 PEGS Europe Summit, 2-6 November in Lisbon, Portugal. Topics include CHO cell line engineering, accelerating recombinant protein production with existing and novel expression platforms, challenges, microRNA manipulation to boost recombinant protein productivity and manufacturing of biopharmaceuticals in Ireland. For more information, please visit http://www.PEGSummitEurope.com/

CHI chats with Tanmoy Mukherjee, M.D., Assistant Clinical Professor, Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital. Dr. Mukherjee discusses the current challenges facing reproductive specialists in regards to genetic diagnosis of recurrent pregnancy loss, as well as how NGS is affecting this type of testing Dr. Mukherjee is one of our speakers for the Clinical Applications for Advanced Testing Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.healthtech.com/reproductive-genetic-diagnostics

CHI interviews Dr. Claudio Hetz, Professor in the Institute of Biomedical Sciences, and Principal Investigator in the Laboratory of Cellular Stress and Biomedicine at the University of Chile about the rapidly evolving drug discovery space of targeting the unfolded protein response (UPR) - particularly for cancers and neurodegenerative diseases. Discussion questions include: • Why has targeting components of the UPR emerged as a viable therapeutic strategy? (What are some of the recent critical discoveries that have propelled this field forward?) • What are emerging and promising therapeutic targets within the UPR and why? • What are some of the current challenges surrounding targeting the UPR? • You are giving a lecture during the upcoming Targeting the Unfolded Protein Response meeting, September 23-24 in Boston. Can you tell us a little about your work and what you hope to convey to attendees during the conference? • What are people within this space just now starting to think about? In other words, where will the greatest attention be over the next few years within this space? To learn more, visit http://www.DiscoveryOnTarget.com/

Bonus Podcast for CHI's interview with Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio Listen to the full podcast here: https://soundcloud.com/chi-podcasts/histone-methyltransferase-and-demethylase-inhibitor-discovery Find more information about the conference here: http://www.DiscoveryOnTarget.com/

CHI interviews Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio about the current challenges in developing novel chemical matter targeting HMTs and HDMs, novel tools and technologies enabling discovery, and emerging targets within this space. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. What are some of the challenges in developing novel chemical matter targeting these enzymes? 3. What are some of the tools and technologies that are aiding epigenetic inhibitor discovery? 4. What are some other interesting and emerging HMT or HDM targets? 5. You are giving a lecture during the upcoming Targeting Histone Methyltransferases and Demethylases meeting, part of Discovery on Target 2015 this September 23-24 in Boston. What do you hope to share with attendees during your lecture? Find more information at http://www.DiscoveryOnTarget.com/

Giulia Siravegna of the University of Torino and the IRCCS-Candiolo Cancer Institute discusses the recent study on the potential of circulating tumor DNA (ctDNA) to evaluate response to chemotherapy in colorectal cancer patients; how ctDNA will be used in conjunction with other tests in the standard of care for colorectal cancer; exciting applications emerging for liquid biopsies; and results from the recent liquid biopsy study published in Nature. Find more at http://www.NextGenerationDx.com/Cell-Free-DNA Watch the interview at https://youtu.be/JHD9YR4NYX0

CHI chats with Raymond J. Langley, Ph.D., Associate Research Scientist, Lovelace Respiratory Research Institute. Dr. Langley discusses his current work on metabolomics risk analysis models for sepsis as well as the challenges associated with them and other developing technology. Dr. Langley is the chair for our Direct Detection for Sepsis session and our Novel Technologies and Approaches session at the Molecular Diagnostics for Infectious Disease conference at the 2015 Next-Generation Diagnostics Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

CHI chats with Kate Simon, Ph.D., Senior Consultant at Biologics Consulting Group, Incorporated. Dr. Simon discusses reference methods for new biomarkers of infectious diseases, how to establish reference methods, and the biggest challenges scientists are facing in this field in 2015 and beyond. Dr. Simon is the chair for our Molecular Point-of-Case Testing For ID session of the Molecular Diagnostics for Infectious Disease track at the 2015 Next-Generation Diagnostics Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

Michael Roehrl of the UHN Program in BioSpecimen Sciences and Anthony Joshua of Princess Margaret Cancer Centre speak to CHI on June 2, 2015. Drs. Roehrl and Joshua will be co-presenting a Case Study of their biobanker/biouser partnership at the Leaders in Biobanking Congress, July 14-16 in Toronto, Canada. Topics include the Rapid Autopsy Program of Princess Margaret Cancer Centre, the mutual influence of lab research and clinical practice work, biospecimen management and collection of robust data, patient contributions to cancer research and understanding cancer therapy resistance. For more information visit http://www.Healthtech.com/Biobanking

CHI chats with Reiner Babiel, Ph.D., who is the Executive Director of Consulting at RBDC. Dr. Babiel discusses NGS in infectious disease diagnostics, key advancements in the field, and the upcoming Next-Generation Diagnostics Summit. Dr. Babiel is the chair for our NGS Sequencing in ID session of the Molecular Diagnostics for Infectious Disease track at the 2015 Next Generation Dx Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

CHI interviews Dr. Xavier Jacq, Head of Biology at MISSION Therapeutics regarding drugging deubiquitinase enzymes (DUBs), a rapidly emerging target class with the Ubiquitin Proteasome System (UPS). Discussion topics and questions include: 1. Tell us a little about MISSION and your current programs. 2. Why are these emerging as viable therapeutic targets? 3. What are drug discovery challenges in this space? What about inhibitor discovery, how challenging is this? 4. What might be challenges surrounding translating these compounds into the clinic? 5. What are some novel tools and technologies being developed to overcome some of these challenges? 6. You are giving a lecture at the 13th Annual Discovery on Target Conference, during the Targeting the Ubiquitin Proteasome System meeting. What do you hope to convey to attendees during your lecture this fall? 7. How have you seen this field evolve over the past few years, and where do you see it going in the future? For more information visit http://www.DiscoveryOnTarget.com/

Suzanne Vercauteren of BC Children’s Hospital and University of British Columbia speaks to CHI on May 20, 2015. Dr. Vercauteren will be a presenter at the Leaders in Biobanking Congress, July 14-16 in Toronto, Canada. Topics include biospecimen collection and storage of clinical data at the BCCH BioBank, practices for ensuring biobank sustainability, ethical and operational considerations of planning an institutional biobank for children and women, and the importance of public engagement. For more information, visit http://www.Healthtech.com/Biobanking

CHI chats with Ally Dering-Anderson, BA, Pharm.D., RP, FAAIM, who is a Clinical Assistant Professor of Pharmacy at the University of Nebraska College of Pharmacy. Ally discusses legal considerations, collaborative care agreements, training, and the changing role of pharmacies. Ally will present a regulatory update for point-of-care diagnostics in the community pharmacy market at the 2015 Next Generation Dx Summit. For details, visit http://www.NextGenerationDx.com/Pharmacy-Diagnostics

Amid Zand interviews Dr. Patrick Hurban of Expression Analysis, a Quintiles Company on 30 April, 2015. Dr. Hurban will be speaking at the Knowledge Foundation & Cambridge Healthtech Institute’s Ninth International Sample Prep Technologies, June 25-26, in Bethesda, MD. His talk will examine use of NGS assays to compare results obtained from matched formalin-fixed and frozen tissue specimens. For more information visit http://www.SamplePrepConference.com/

CHI interviews Dr. Gabriela Chiosis, Associate Member and Lab Head of Molecular Pharmacology and Chemistry at Memorial Sloan Kettering Cancer Center about the trends, tools and challenges in developing chaperome-based therapeutics. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. Can you share with us what we have learned from discovery and clinical efforts thus far? 3. What tools have recently been developed, including those from your lab, that are currently advancing drug discovery in this space? 4. What are the remaining challenges surrounding drug discovery and development in this space? What has hindered FDA approvals? 5. You are giving a lecture during the upcoming Chemical Biology for Target Validation meeting, June 10-11 in Boston – part of the World Pharma Congress 2015. What do you hope to convey to attendees during your lecture? 6. Where do you see the greatest opportunities for continued development? For more information visit http://www.Healthtech.com/Chemical-Biology-Proteomics

Mark Coflin, Senior Director of Alliance Management at Baxter Bioscience discusses his views on the changes in the alliance management landscape, the evolution of the AM function to meet growing demand, challenges in this space, and Baxter Bioscience’s new start in building world-class alliance management capabilities. For more information visit http://www.Healthtech.com/AMS

The field of immunotherapy is very exciting and holds great promise. This podcast will review limitations of monotherapy, and describe Dr. Curran’s approach for inducing an immune response through combination therapy. He will explain how this approach different from existing approaches and how it uses new strategies to overcome common limitations. Advice will be shared for selecting immunotherapy combinations and review applications emerging in combination therapy that are not possible with monotherapy. For more information go to http://www.PEGSummit.com/

Caroline Bennette of the Group Health Research Institute speaks to CHI on April 3, 2015. Dr. Bennette will be a presenter at TCGC: The Clinical Genome Conference, June 22-24 in San Francisco, CA. Topics include determining the cost effectiveness of returning incidental findings from next-generation sequencing to patients, challenges faced when developing analytic tools and policy models to aid decision-making in oncology and Patient-Centered Outcomes Research at the Group Health Research Institute. For more information visit http://www.ClinicalGenomeConference.com/

James L. Sherley of Asymmetrex (launched in 2013 as “The Adult Stem Cell Technology Center (ASCTC)”) speaks to CHI on March 16, 2015. Dr. Sherley will be presenting during the 3D Cellular Models conference at the 2015 World Preclinical Congress, June 10-12 in Boston, MA. Topics include asymmetric self-renewal of tissue stem cells, p53 regulation, stem cell kinetics dynamics and the dimension of time, incorporating cell turnover into 3D cellular models, and combining computer simulation and primary tissue cell culture for drug toxicity research.

Krista Woodley of Biogen speaks to CHI on March 12, 2015. Ms. Woodley will be presenting during the Cloud Computing and Data Security tracks at Bio-IT World Conference & Expo, April 21-23 in Boston, MA. Topics include IT risk management and regulatory compliance in the life sciences, how the rise of cloud-based computing has altered data security management, compliant cloud computing and more.

Elizabeth D. Buttermore of Boston Children's Hospital and Harvard Medical School speaks to CHI on March 27, 2015. Dr. Buttermore will be presenting during the 3D Cellular Models conference at the 2015 World Preclinical Congress, June 10-12 in Boston, MA. Topics include how human-derived neurons enhance preclinical phenotypic screening, heterologous expression systems, translational research and the potential of pain models and peripheral neuropathy research for drug development. Find more at http://www.WorldPharmaCongress.com/

Nathaniel Pearson of the New York Genome Center speaks to CHI on March 17, 2015. Dr. Pearson will be a keynote presenter at TCGC: The Clinical Genome Conference, June 22-24 in San Francisco, CA. Topics include biological and genomic diversity, the evolution of systems over time, the New York Genome Center’s leveraging of citizen data, the value of participatory science on genomic research, applying big data management lessons from other fields to genomics for long-term healthcare and more. For more information visit http://www.ClinicalGenomeConference.com/

CHI sits down with Dr. Mike Makrigiorgos of Dana Farber and Brigham to discuss a new COLD-PCR method (temperature tolerant COLD-PCR) that uses targeted re-sequencing to detect mutations as low as .01-.1%. In this podcast, Dr. Makrigiorgos discusses the science behind COLD PCR, gives a preview of his talk at the April cfDNA conference in Lisbon, and discusses the future impact of liquid biopsy.

Laura J. van ’t Veer of University of California, San Francisco speaks to CHI on March 4, 2015. Dr. van ‘t Veer will be a keynote presenter at TCGC: The Clinical Genome Conference, June 22-24 in San Francisco, CA. Topics include the genetic makeup of breast cancer tumors and personalized medicine; transdisciplinary research collaborations related to the MammaPrint test; molecular genomic data integration, cancer patient therapy and survival prediction. For more information visit http://www.ClinicalGenomeConference.com/

John Conley of UNC and Robinson Bradshaw & Hinson speaks to CHI on March 3, 2015. Dr. Conley will be presenting during the IT Infrastructure – Hardware, Software Development, Cloud Computing and Data Security tracks at Bio-IT World Conference & Expo, April 21-23 in Boston, MA. Topics include data security and privacy at large health research institutes vs. smaller biotech companies, plus changes to international data privacy regulations and differences between the U.S. and European Union. Find more at: http://www.Bio-ITWorldExpo.com/

This podcast presents an interview with Dr. John Kellie, an Investigator in the Bioanalytical Sciences and Toxicokinetics group at GlaxoSmithKline, and a speaker in the Characterization of Biotherapeutics meeting at the 11th Annual PEGS Boston. John explains how next-generation analytical technologies are being used to characterize circulating ADC species, and how these findings support the development of safe and effective antibody-drug conjugate therapeutics. To learn more, visit http://www.PEGSummit.com/Biotherapeutics-Characterization

Mimi Langley interviews Dr. Jon Lai, Associate Professor at Albert Einstein College of Medicine on February 4. Dr. Lai will be speaking during the Phage & Yeast Display conference at PEGS China Summit, taking place March 31-April 2 in Shanghai, China.

Dave Peterson of Kaiser Permanente speaks to CHI on February 3, 2015. Mr. Peterson will be a panelist during the IT Infrastructure – Hardware, Software Development, Cloud Computing and Data Security tracks at Bio-IT World Conference & Expo, April 21-23 in Boston, MA. Topics include IT compliance and managing vendor-related data security risks, the value of regulations alongside technological innovation, balancing patient privacy with biological research needs, reporting on controls effectiveness for service providers and more. http://www.Bio-ITWorldExpo.com/

David Barton will discuss the new regulations being developed, which have major implications for IVD manufacturers and for laboratory-developed tests. This podcast will give an overview of the proposed new IVD regulation, a timeline for development, and briefly discuss how it will impact IVD manufacturers and clinical labs.

Dr. Mark Gerstein of Yale University speaks to CHI on January 16, 2015. Dr. Gerstein will be a speaker during the Clinical Genomics track at Bio-IT World Conference & Expo, April 21-23, 2015 in Boston, MA. Topics include evolving data science applications to genomics, the utility of networks for biological data analysis and integration, studying non-coding mutations for cancer genomics and personal genomics research, the computational tool FunSeq and more. http://www.bio-itworldexpo.com/

CHI's Samantha Lewis speaks with Daniel Kerls, director of ambulatory operations at CVS' Minute Clinic, as well as Alexander Sbordone, who is the Minute Clinic operations manager at CVS. Kerls and Sbordone discuss staffing MinuteClinic, the types of diagnostic tests they seek out, and the future direction of rapid clinics. Connect with CVS MinuteClinic’s Operations Manager, Alexander Sbordone, for an update on the challenges and expanding opportunities for testing in a retail pharmacy setting at the 2015 Next Generation Dx Summit. For details, visit http://www.nextgenerationdx.com/pharmacy-diagnostics

Amid Zand Interview Ms. Nariman Nasser of Genentech, on December 23, 2014. Nariman will be speaking at the SCOPE Summit in Orlando, FL in a track titled managing late stage research, observational studies and registries. Her talk will focus on digital strategies that makes observational studies more accessible and better aligned with patients lives.

Amid Zand Interview Dr. Vera Ehrenstein of Aarhus University (Denmark) on December 27, 2014. Dr. Ehrenstein will be speaking at the SCOPE Summit in Orlando, FL in a track titled managing late stage research, observational studies and registries. Her talk will focus on collaborating with regulatory bodies such as the EMA on risk-minimization studies.

The University of Pittsburgh Medical Center’s Liron Pantanowitz, Douglas Hartman, and Jeffrey Fine discuss the future of digital pathology, what they are most looking forward to at CHI’s Digital Pathology conference, changes in the field, highlights from their presentations in February, as well as how UPMC has become a leading organization in digital pathology.

Interview with Moderator of the Inaugural Swimming with the Sharks competition, for start-ups to compete for venture funding in the genomic space.

Amid Zand Interview Dr. Sundos Hamza of InterMune on December 12, 2014. In this interview Dr. Hamza speaks about the importance of effective global drug safety risk minimization strategies in clinical and post marketing phases of drug development.

Dr. Lois Lampson, an Associate Professor of Neurosurgery at Brigham and Women’s Hospital, describes novel ways of approaching the targeting of the brain (and brain cancers) using Antibody Therapeutics. Dr. Lampson is a speaker in the Cancer Targets for Antibody Therapeutics meeting being held at the 14th annual Peptalk on January 19-23, 2015 in San Diego. To view speaker abstracts and register for the meeting, please visit http://www.CHI-PepTalk.com

Dr. Donald Jarvis of University of Wyoming and GlycoBac, LLC and Dr. Dominic Esposito of Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. speak to CHI in November 2014. Drs. Jarvis and Esposito will be speakers during the Transient Protein Production conference at PepTalk, January 19-23, 2015 in San Diego, CA. Topics include the benefits of protein processing in the baculovirus-insect cell system, future challenges for transient protein expression and production and possible solutions.

Dr. Nathan E. Lewis of the Novo Nordisk Foundation Center for Biosustainability at UCSD School of Medicine speaks to CHI on November 3, 2014. Dr. Lewis will be a speaker during the Recombinant Protein Expression and Production and CHO Cells conferences at PepTalk, January 19-23, 2015 in San Diego, CA. Topics include the promise and challenges of using Chinese hamster ovary cells for enhancing recombinant protein expression and production, the creation of computational models by integrating metabolism glycosylation and the protein secretion pathway, the Novo Nordisk partnership with University of California, San Diego and more.

Dr. Joshua LaBaer of Arizona State University speaks to CHI on October 27, 2014. Dr. LaBaer will be a keynote speaker during the Recombinant Protein Expression and Production conference at PepTalk, January 19-23, 2015 in San Diego, CA. Topics include applications of sequence-verified recombination-based clone sets to high-throughput protein expression, cell-free expression systems, sharing clones upon request for research, self-assembling protein microarrays and more.

Nandini Kashyap interviews Dr. Daniel L. Norwood of Boehringer Ingelheim Pharmaceuticals on October 15, 2014. Dr. Norwood will be speaking during the 3rd Annual Extractables and Leachables conference which takes place on January 22-23 at the upcoming PepTalk event which runs from January 19th to 23rd, 2015 in San Diego, CA. Topics Include: Extractable, Leachable, PQRI – PODP, United States Pharmacopeia, FDA, Parenteral and Ophthalmic Drug Products, Single use technologies, Risk assessment, Analytical Study design for E&L, Regulatory consideration, Toxicological considerations, Cell Culture, Plastic Packaging Systems, Pharmaceutical Packaging/Delivery Systems, multi-product facilities , Leachables in Large Volume Parenteral Products

Nandini Kashyap interviews Dr. Johnson Varghese of Shire HGT on October 1, 2014. Dr. Varghese will be speaking during the Characterization of ADCs, Bispecifics and New Biotherapeutics conference taking place on January 19th-20th at the upcoming PepTalk event which runs from January 19th to 23rd, 2015 in San Diego, CA.

Amid Zand interviews Mr. John Warren of McDermott Will & Emery on 23 September, 2014. Mr. Warren will be speaking at the Evidence-Based Reimbursement Summit, November 17 to 19, in Bethesda, MD. His talk will be focused on examining speed bumps and road blocks in Medicare payments for diagnostics.

Amid Zand interviews Dr. Gregory Hess of University of Pennsylvania on 17 September, 2014. Dr. Hess will be speaking at the Evidence-Based Reimbursement Summit, November 17 to 19, in Bethesda, MD. His talk will examine the growth of pharmacogenetic testing and interventions.

Dr. John P. Wikswo of Vanderbilt University speaks to CHI on September 8, 2014. Dr. Wikswo will be a keynote speaker during the Engineering Functional 3D Models and Organotypic Culture Models for Toxicology conferences at the FAST Congress, November 17-19 in Boston, MA. Topics include the evolution of tissue- and organ-scale toxicology research, the need for microfluidics in biological physics to control systems, challenges with organs-on-a-chip efforts, the hermeneutic circle of biology and more.

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases

Dr. Kristin Fabre of NCATS at the National Institutes of Health speaks to CHI on September 3, 2014. Dr. Fabre will be a keynote speaker during the Engineering Functional 3D Models and Organotypic Culture Models for Toxicology conferences at the FAST Congress, November 17-19 in Boston, MA. Topics include NCATS’s Tissue Chip for Drug Screening Program, increased government support for tissue and organ chips, the benefits of these models for drug research, opening the drug discovery bottleneck through human surrogate technology and more.

Amid Zand interviews Dr. Kim Lewis of Northeastern University on August 14, 2014. Dr. Lewis will be speaking at the Re-Entering Antibacterial Drug Development Summit, October 27 to 29, in Boston, MA. His talk will be on the subject of Sterilizing Antibiotics.

Amid Zand interviews Dr. Prabhavathi Fernandes of Cempra, Inc. on August 14, 2014. Dr. Fernandes will be speaking at the Re-Entering Antibacterial Drug Development Summit, October 27 to 29, in Boston, MA. Her talk will be focused on the development of an antibiotic with broad indications.

In a recent interview, Cambridge Healthtech Institute spoke with Dr. Jialiang Wang about his outlook on targeting BET Bromodomains in Cancer. Questions included: 1. Part of your research focuses on epigenetic therapeutic approaches, particularly for glioblastoma tumors, where targeting BET bromodomains are of interest. Can you speak to us a little about the underlying biological/genetic rationale for researchers targeting these proteins in glioblastoma tumors? 2. Since your work also aims to develop novel therapeutic drugs, what initial approaches have you taken to validate BET bromodomains as both druggable and potentially efficacious targets? What early signs of efficacy are you noticing in vivo? 3. One important consideration when thinking about drugging individual BET proteins is unintended consequences of inhibition as they have known roles as co-repressors as well as co-activators. Do you have such concerns? What do you notice during your work? Do you have potential concerns of toxicity for these inhibitors now in early human testing? 4. What is your outlook for the potential hurdles developers will face who are starting to target BET bromodomains? What are current challenges that need to be overcome to help maximize their potential benefit for patients? Dr. Jialiang Wang will be discussing this in more depth at Discovery on Target’s Targeting Epigenetic Readers and Chromatin Remodelers Conference. Learn more at http://www.discoveryontarget.com/Epigenetic-Readers

An-Dinh Nguyen interviews Carolyn Compton of National Biomarkers Developmental Alliance, Complex Adaptive Systems Institute, Mayo Medical School and Arizona State University on July 23, 2014. Dr. Compton will be a plenary keynote speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA. Topics include effects of pre-analytical variables on human biospecimens during acquisition and processing, the importance of fit-for-purpose samples and how biobanks play a role in making personalized cancer therapies possible.

An-Dinh Nguyen interviews Colin C. Pritchard of University of Washington on July 21, 2014. Dr. Pritchard will be speaking at Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change, September 15-17 in Seattle, WA. Topics include clinical applications of next-generation sequencing gene panels for cancer risk assessment and precision treatment, collaborating with Dr. Mary-Claire King, overcoming challenges in translating genetic information into clinical settings, ensuring such data benefit individual patients and more.

An-Dinh Nguyen interviews James M. Olson of Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital, Presage Biosciences and Blaze Bioscience on July 18, 2014. Dr. Olson will be a plenary keynote speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA. Topics include the scorpion venom-derived molecular imaging agent Tumor Paint and its potential applications for cancer treatment, optide therapeutics, drug research and development breakthroughs in pediatric brain tumors through PDX models and more.

The panelists describe what they will be covering during the panel discussion, which include third party payer requirements for clinical utility and funding sources. They will also review how the higher level of evidence will impact implementation, equity and access.

An-Dinh Nguyen interviews Stephen Schmechel of NWBioTrust and University of Washington on July 17, 2014. Dr. Schmechel will be a short course instructor for Biobanking Is More than Sample Storage and Management and speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA. Topics include critical business considerations for running biobanks to advance personalized medicine, support of translational research and clinical trials through a biobanker/biouser partnership and collaborations between University of Washington, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital and elsewhere.

Amid Zand interviews Dr. Richard White of Genomic Health on June 11, 2014. Dr. White will be speaking at the Companion Diagnostics: Technology and Reimbursement track at the Next Generation Dx Summit, August 19-21, in Washington, D.C.

An-Dinh Nguyen interviews James Hicks of Cold Spring Harbor Laboratory on June 24, 2014. Dr. Hicks will be a speaker at the Single-Cell Sequencing conference, part of the Next-Generation Dx Summit, August 19-21 in Washington, DC. Topics include the advantages of single-cell genomic analysis for personalizing cancer therapies, one method for making single-cell sequencing more cost efficient, the relationship between tumor heterogeneity and drug response and more.

An-Dinh Nguyen interviews Jan Vijg of Albert Einstein College of Medicine on June 12, 2014. Dr. Vijg will be a featured speaker at the Single-Cell Sequencing conference, part of the Next-Generation Dx Summit, August 19-21 in Washington, DC. Topics include the evolution of single-cell sequencing technologies from microarrays through next-generation sequencing, improvements to amplification, challenges researchers still face, detection of somatic mutations in tumor tissues, single-cell analysis of aging and more.

Dr. Kimberly Strong of the Medical College of Wisconsin speaks to CHI patient attitudes towards receiving genomic information, access to information, and the future of genomic medicine. Dr. Strong will be speaking at Cambridge Healthtech Institute’s Inaugural Inherited Disease Diagnostics Conference, taking place August 19-20, 2014 in Washington, DC as part of the Next Generation Dx Summit. Learn more at http://www.nextgenerationdx.com/Inherited-Disease-Diagnostics

Dr. Bruce Korf of the University of Alabama at Birmingham speaks to CHI about some of the educational challenges in genomic medicine implementation, the educational needs of physicians, and how he sees genomics being used clinically. Dr. Korf will be speaking at Cambridge Healthtech Institute’s Inaugural Inherited Disease Diagnostics Conference, taking place August 19-20, 2014 in Washington, DC as part of the Next Generation Dx Summit. Learn more at http://www.nextgenerationdx.com/Inherited-Disease-Diagnostics

Kip Harry, Conference Director at Cambridge Healthtech Institute discusses Ubiquitin Proteasome System drug discovery with Dr. Benedikt Kessler, Ph.D., University Research Lecturer, Ubiquitin Proteolysis Group, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford Discussion Questions Include: • What are the most present opportunities in this space? (Another way to ask that): What are some of the most promising UPS targets currently being investigated, and within which indications? • What challenges have slowed the progress of generating lead molecules targeting various components of the UPS? • Why are Deubiquitinases (DUBs) emerging as viable therapeutic targets? • Are there drug discovery challenges specific to targeting DUB enzymes vs. ligases? If so, what are they? • What are some novel tools and technologies being developed/implemented to overcome some of these challenges? • What do you hope to convey to attendees during your lecture this fall at the Ubiquitin Proteasome System meeting? • What is on the horizon for research in this space? (Another way to ask that): What are future goals that need to be accomplished to push these novel medicines further into the clinic?

Dr. Teri Melese, Associate Professor of Medicine, and Assistant Vice Chancellor of Industry Alliances at the University of California, San Diego shares insights into the evolution, challenges, opportunities, and outlook for academic-industry partnerships. Dr. Melese will be moderating a discussion on this topic during the 11th Annual Strategic Alliance Management Congress, taking place, May 5-7, 2014 in Philadelphia. She'll be joined by a notable panel of the industry's best, including Anthony Marshall of IBM, Sylvaine Cases of Sanofi-Aventis, Noah Leibowitz of Simpson Thacher & Bartlett, and Yvonne Tran of Schrödinger. Learn more about the event at http://www.healthtech.com/ams Discussion questions include: What changes have been noted with these types of partnerships over the past decade? What challenges exist that are harder to overcome? What are clear-cut and feasible opportunities? What will the panel discussion Optimizing the Impact of Academic-Industry Alliances on Innovation convey to attendees during the 11th Annual Strategic Alliance Congress? What is the outlook for the ways in which these partnerships will continue to evolve? What does this mean for stakeholders involved?

An-Dinh Nguyen interviews Valerie A. Schneider of the National Center for Biotechnology Information (NCBI), NIH on April 4, 2014. Dr. Schneider will be a speaker at TCGC: The Clinical Genome Conference, June 10-12, 2014 in San Francisco, CA. Topics include updates to the human reference genome assembly, the Genome Reference Consortium (GRC), the relationship of the assembly to annotation and genome browsers, new assembly features and their potential impact on clinical analyses and interpretation of results.

An-Dinh Nguyen interviews John Pfeifer of Washington University School of Medicine on April 3, 2014. Dr. Pfeifer will be a keynote speaker at TCGC: The Clinical Genome Conference, June 10-12, 2014 in San Francisco, CA. Topics include factors that have prevented payers from reimbursing clinical next-generation sequencing testing by laboratories, the evolution of reimbursement models for labs, tailoring testing to ensure payment by insurance companies, clinical NGS to enhance patient care and more. http://www.clinicalgenomeconference.com/TCGC_content.aspx?id=134465&libID=134413

CHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.

An-Dinh Nguyen interviews David Galas of Pacific Northwest Diabetes Research Institute on March 27, 2014. Dr. Galas will be a keynote speaker at TCGC: The Clinical Genome Conference, June 10-12, 2014 in San Francisco, CA. Topics include the challenges of translating genomic data into diagnostics and therapeutics, the promise of computational biology approaches for overcoming those barriers, the possible impact of extracellular RNA and the microbiome on human biology and more.

Christina Lingham interviews on Luis Álvarez-Vallina of Aarhus University on March 27, 2014. Dr. Álvarez-Vallina will be speaking at the Phage and Yeast Display track at PEGS, on May 5-6 in Boston, Mass. Topics include phage display, in vivo selection of antibodies. tumor targeting, novel tumor-associated antigens, antibody-based therapeutics, targeted delivery.

Nandini Kashyap interviews Dr. Geeti Gangal of Novartis Institutes for Biomedical Research on March 26, 2014. Dr. Gangal will be speaking during the 2nd Annual Formulation and Drug Delivery conference which is taking place on May 21-22, 2014 as part of World Pharma Congress in Boston, MA Topics Include: Poor Solubility, Bioavailability, Oral Drug delivery, Preclinical animal models, Drug Absorption, Dissolution Prediction and Experimentation, Discovery and development interface, Solubilization, Formulation material science, Enabling formulation, Enabling technologies, Nanotechnology, Characterization, Drug and Product stability, In vitro-In vivo correlation (IVIVC) .

Christina Lingham interviews Rakesh Dixit of MedImmune on March 26, 2014. Dr. Dixit will be speaking at the Advancing Bispecific Antibodies to the Clinic for Oncology track at PEGS, on May 7-8 in Boston, Mass. Topics include bispecific antibodies for oncology, engineering innovations for engineering bispecific antibodies, and bispecific platforms currently under development.

Nandini Kashyap interviews Dr. Nicholas Meanwell, Executive Director of Department of Chemistry at Bristol-Myers Squibb Co. on March 25, 2014. Dr. Meanwell will be delivering keynote presentation during the 3rd Annual Property-Based Drug Design, May 22-23, 2014 at Westin Boston Waterfront Hotel in Boston, MA. Topics Include: Physicochemical properties in drug discovery and development, Bio-physical properties, Property based drug design, drug design, Solid State properties, Solubility, Permeability, Lipophilicity, Physicochemical descriptors, High-Throughput Physicochemical Screens, Developability of molecules, Polymorphism, Discovery workflow

Christina Lingham interviews Robert Mabry of Adimab on March 25, 2014. Dr. Mabry will be speaking at the Engineering Bispecific Antibodies track at PEGS, on May 8-9 in Boston, Mass. Topics include common issues and engineering solutions for engineering bispecific antibodies, emerging applications for bispecifics and the growth of bispecific platforms currently under development.

Kip Harry, Conference Director at Cambridge Healthtech Institute discusses epigenetic drug discovery with Dr. Matthew Fuchter, Senior Lecturer of Synthetic and Medicinal Chemistry at the Imperial College London. Questions Include: • From an inhibitor development standpoint, what methods do you use for discovery to lead? • Why do you choose natural products to aid in targeting epigenetic modifiers and is there limited chemical matter in this space? • What opportunities are there for infectious disease and other indications? • What has ignited all this interest in developing second generation epigenetic inhibitors – particularly targeting Histone Methyltransferases, Demethylases and BET Bromodomains? • Have we learned anything from approved compounds? • What are major challenges seen in the development of novel epigenetic inhibitors? • What about safety and toxicity of compounds – is this a major concern? • What talks/topics are you looking forward to during the Epigenetic Inhibitor Discovery Meeting? • How quickly can we expect to see these novel medicines reaching patients in need? • Is combination therapy where we will see the greatest impact in this space? • Some compare the epigenetic enzymes to kinases, where they will provide years of fertile grounds for discovery. What do you think?

Dr. Gerald Tanoury from Vertex, featured speaker at CHI's 'Efficient Process Chemistry' meeting May 22-24, 2014 in Boston, speaks about dealing with two challenging chemical steps in the scale-up of HCV protease inhibitor, Telaprevir, which was launched in 2011 as a new treatment for hepatitis C infection. Tanoury also discusses Telaprevir's route development in the context of his views on what makes an efficient route and shares with the interviewer, Dr. Anjani Shah, Conference Director for CHI, what he is interested in learning more about at the meeting.

Dr. Erlanson of Carmot Therapeutics and Dr. Zartler of Tessera Consulting speak with CHI's Dr. Shah on March 14, 2014 about new strategies for fragment linking, different companies' fragment-based campaigns, and types of PPI-directed compounds advancing in the clinic. Dr. Erlanson will be speaking at the Fragment Based Drug Discovery meeting on April 24-25, 2014 in San Diego, part of CHI's Drug Discovery Chemistry event about Fishing for Fragments to Complement Known Binders. Dr. Zartler was the scientific advisor to Dr. Shah for the Protein-Protein Interactions meeting taking place April 23-24, 2014 in San Diego, part of CHI's Drug Discovery Chemistry event. Drs. Erlanson and Zartler are also co-instructors of one of the dinner workshops at the event, Advancing Tools and Technologies for Fragment-Based Design on April 24, 2014. Erlanson and Zartler are also co-editors of the Practical Fragments blog: http://practicalfragments.blogspot.com/

An-Dinh Nguyen interviews Benjamin Breton and Mark Adams of Good Start Genetics on March 7, 2014. Mr. Breton and Dr. Adams will be co-instructing the pre-conference workshop, An Embarrassment of Riches: Choosing and Implementing Cloud Infrastructure to Replace On-Premises HPC for Next-Generation Sequence Analysis, and Dr. Adams will be speaking during a shared session for the Cloud Computing and Data Security meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include optimizing genome sequencing data projects via cloud-based computing, the evolution of commercial bioinformatics efforts that manage genomic and genetic data, challenges ranging from systems integration to legal and regulatory requirements in clinical settings and more.

This May 21-22 at the Structure-Based Drug Design conference in Boston, Dr. Jason Burch, a Medicinal Chemist at Genentech will give a talk on structure-based design and property optimization of potent and selective pyrazole carboxamide interleukin-2 inducible t-cell kinase (itk) inhibitors for the treatment of inflammatory diseases. CHI recently spoke with Dr. Burch about why he chose to pursue ITK inhibitors, important considerations for developing these types of inhibitors, and what techniques were used to improve pharmaceutical properties of the lead matter. Dr. Burch also discusses how advances in genomics and demand for personalized treatments has changed drug design techniques.

An-Dinh Nguyen interviews Christopher Mason of Weill Cornell Medical College on February 21, 2014. Dr. Mason will be speaking during the Clinical Genomics meeting at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the use of bioinformatics methods in genomics to study diseases, researching the human genome’s functional elements through aggressive tumors and other extreme cases, applying an evolutionary perspective and more. Learn more at: http://www.bio-itworldexpo.com

An-Dinh Nguyen interviews Avi Ma’ayan of Icahn School of Medicine at Mount Sinai on February 20, 2014. Dr. Ma’ayan will be a featured speaker during the shared session for the Systems Pharmacology and Cancer Informatics meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the emergence of systems biology in drug research, promising datasets that can accelerate drug discovery and personalized medicine, methods for extracting knowledge from data, the potential research impact of systems pharmacology and more. Join Dr. Ma'ayan and a focused group of Systems Pharmacology Researchers at Bio-IT World 2014. Learn more about the program at http://www.Bio-ITWorldExpo.com/Systems-Pharmacology

Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute, interviews Dr. Nhut Diep of Forest Laboratories on February 19, 2014. Dr. Diep will be speaking during the 7th Annual 'Efficient Process Chemistry' conference taking place May 22-23, 2014 as part of CHI's World Pharma Congress May 21-23 in Boston, MA. Efforts to identify a scalable process for preparing DPP-IV inhibitor compounds (diabetes therapeutic) led to the discovery of several useful transformations, including the asymmetric lithiation-boronation of the Boc-pyrrolidine that provided a single compound; the development of a streamline-telescope coupling reaction and workup which led to a robust crystallization/purification method.

Nandini Kashyap interviews Dr. Robert A. Bellantone of Long Island University on February 17, 2014. Dr. Bellantone will be speaking during the 2nd Annual Formulation and Drug Delivery conference taking place May 21-22, 2014 as part of World Pharma Congress in Boston, MA Poor Solubility, Bioavailability, Oral Drug delivery, Solubilization, Formulation material science, Solid state characterization, Dissolution Prediction and Experimentation, Drug and Product stability, Drug form stability, In vitro-In vivo correlation (IVIVC), Excipient-water interaction, Excipient drug interaction

An-Dinh Nguyen interviews William Telford of Sanofi on February 14, 2014. Mr. Telford will be a speaker during the shared session for the Data Security, IT Infrastructure – Hardware and Software Development meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the evolution of data security strategies for pharmaceutical companies and life science collaborators, data classification to determine risk levels and protections, security challenges unique to the pharma industry and more.

An-Dinh Nguyen interviews Ravi Madduri of University of Chicago and Argonne National Laboratory on February 10, 2014. Mr. Madduri will be a speaker during the shared session for the Cloud Computing and Next-Gen Sequencing Informatics meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the improvement of large-scale NGS analysis on the cloud, data management challenges life science researchers face, strategies and technologies for increasing scientists’ productivity and more.

An-Dinh Nguyen interviews Hugo Geerts of In Silico Biosciences and University of Pennsylvania on February 7, 2014. Dr. Geerts will be a speaker during the Systems Pharmacology conference at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the limitations of translating outcomes from models for clinical utility, the application of computer-based methods to pharmaceutical R&D to improve predictability of clinical trials, the complexities of researching and developing drug therapies for the central nervous system and more.

Nandini Kashyap interviews Dr. William P. Beierschmitt, Ph.D., DABT, FATS, Regulatory Strategy Lead at Pfizer on December 20, 2013. Dr. Beierschmitt will be speaking during the 2nd Annual Extractables and Leachable conference taking place January 16-17 as part of PepTalk, January 13-17 in Palm Springs, CA. Topics include early adoption of toxicological risk assessment, risk assessment strategy, patient safety, safety issues related to extractables and leachables, role of toxicologist, plastic single use bioreactors, single use systems, risk based assessment, extractable testing, flexible manufacturing, process and product development, BPOG, USP, PQRI, standardized E&L testing, predication of leachable, toxicity and safety.

Nandini Kashyap interviews Dr. Yasser Nashed-Samuel, Principal Scientist, Amgen on December 6, 2013. Dr. Yasser Nashed-Samuel will be speaking during the 2nd Annual Extractables and Leachable conference taking place Jan16-17 as part of PepTalk, January 13-17 in Palm Springs, CA. Topics include a case study on E&L from single use bioreactors, E&L impact on cell culture performance, plastic single use bioreactors, single use systems, risk based assessment, extractable testing, flexible manufacturing, process and product development, , BPOG, USP, PQRI, standardized E&L testing, predication of leachable, toxicity and safety.

Nandini Kashyap interviews T.N. Thompson, President, Millrock Technology on December 6, 2013. Mr. Thompson will be speaking during the 7th Annual Lyophilization and Emerging Drying Technologies conference taking place Jan15-16 as part of PepTalk, January 13-17 in Palm Springs, CA. Topics include freeze drying, process control and monitoring for the freezing and primary drying phases, cycle development and process control, controlled nucleation, heat flow, reduction in drying cycle’s time.

Nandini Kashyap interviews Dr. William J. Lambert of MedImmune on December 6, 2013. Dr. Lambert will be speaking during the 4th Annual Protein Device Combinations conference taking place Jan 15-16, 2014 as part of PepTalk, January 13-17 in Palm Springs, CA. Protein Delivery, large volume delivery, bolus injections, delivery devices such as pens and auto injectors for drug delivery, high viscosity injectors, protein device combinations, protein and peptide products, pen injectors, pen needles and auto-injectors for self-injection, integration of formation and devices.

Nandini Kashyap interviews Jeffrey Breit, Ph.D of Bend Research on November 15, 2013. Dr. Breit will be speaking during the Lyophilization and Emerging Drying Technologies conference at the PepTalk, January 13-17 in Palm Springs, CA. Topics include using a vaccine formulation development, room temperature stability, use of spray drying, emerging drying technologies

Nandini Kashyap interviews Prof. Thomas Laue of University of New Hampshire on November 19, 2013. Prof. Laue will be speaking during the Protein Aggregation and Emerging Analytical Tools conference at the PepTalk, January 13-17 in Palm Springs, CA. Topics include protein aggregation, mechanism of protein aggregation, non-covalent interactions, hydrophobic effect, dipole-dipole interactions, effect of viscosity, development of analytical tools for aggregate detection, progress in the field of protein aggregation.

Nandini Kashyap interviews Jeffrey Breit, Ph.D of Bend Research on November 15, 2013. Dr. Breit will be speaking during the Lyophilization and Emerging Drying Technologies conference at the PepTalk, January 13-17 in Palm Springs, CA. Topics include using a vaccine formulation development, room temperature stability, use of spray drying, emerging drying technologies.

An-Dinh Nguyen interviews Sriram Kosuri of UCLA on November 11, 2013. Dr. Kosuri will be a keynote speaker during the Engineering Genes, Vectors, Constructs and Clones conference at PepTalk 2014, January 13-17 in Palm Springs, CA. Topics include the effect of codon usage on protein expression, the reliance on bacteria for biological engineering research, new tools like CRISPR for studying more eukaryotic systems, next-generation gene synthesis, work at the Wyss Institute and more.

An-Dinh Nguyen interviews Zhimei Du of Amgen on November 1, 2013. Dr. Du will be speaking during the Recombinant Protein Expression and Production conference at PepTalk 2014, January 13-17 in Palm Springs, CA. Topics include unfolded protein response, pathways for increasing recombinant protein production and expression yield, understanding cell status, UPR’s dynamic nature and cell line development at Amgen.

Lab-on-a-chip (LOC) devices have a tremendous potential for revolutionizing personal health. In developing countries, mobile diagnostics provide immediate diagnosis in the field, and in the U.S., patients and consumers can have greater access to traditionally complex diagnostics. CHI recently spoke with Dr. Samuel Sia of Columbia University about his latest projects at Columbia and the evolution of microfluidic technology. Dr. Sia also discusses how he sees mobile diagnostics playing a role in the future of medicine.

An-Dinh Nguyen interviews Sabine Geisse, Ph.D., Director/NLS, Novartis Institutes for BioMedical Research on October 31, 2013. Dr. Geisse will be a keynote speaker during the Transient Protein Production conference at PepTalk 2014, January 13-17 in Palm Springs, CA. Topics include the importance of considering cellular environments when working on genes and molecular biology, the evolution of biotechnology, recombinant production of increasingly complex biomolecules and more.

An-Dinh Nguyen interviews Joseph Kittle of Ohio University and Molecular Technologies Laboratories, LLC on October 30, 2013. Dr. Kittle will be a speaker during the Engineering Genes, Vectors, Constructs and Clones conference at PepTalk 2014, January 13-17 in Palm Springs, CA. Topics include problems with plasma-based protein expression, using engineered bacteria and chromosomally inserted genes, integrating current biotech industry knowledge with academic biochemistry and molecular engineering instruction and more.

An-Dinh Nguyen interviews Zoltan Szallasi of Harvard Medical School and Danish Technical University on 23 October 2013. Dr. Szallasi will be speaking during the Genome Informatics conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal. Topics include: • Clinical Validation and Analysis of Cancer Genomic Data • Computational and Experimental Methods for Detecting Genomic Instability • Quantifying Homologous Recombination in Tumor Biopsies • Platinum Sensitivity in Breast Cancer • Adapting to Next-Generation Sequencing

An-Dinh Nguyen interviews Anne Cambon-Thomsen of CNRS on 23 October 2013. Dr. Cambon-Thomsen will be a keynote speaker during the Genome Informatics conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal. Topics include: • Interdisciplinary Aspects of Public Health Research • Ethical, Societal and Legal Issues • Applications of Immunogenetics Research • Genomic Data Sharing vs. Privacy Protection

CHI talks to Syapse Founder and President, Jonathan Hirsch, about their software platform, how cloud-based technologies have evolved, and current challenges and opportunities. Jonathan also discusses how the Syapse platform is being used clinically and how he sees the role of clinicians evolving as technology becomes more accessible. Jonathan Hirsch will be speaking at the Genomics in Medicine Symposium this February 13-14 in San Francisco as part of the Molecular Medicine Tri-Con.

: An-Dinh Nguyen interviews Heidi Carmen Howard of Radboud University Medical Centre and INSERM on 16 October 2013. Dr. Howard will be speaking during the Genome Informatics conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal. Topics include: • The Translation of Genetic Data into the Clinic • The Necessity of Ethical, Social and Legal Considerations in Genomics • Genetics for Consumers, Patients and Public Health

An-Dinh Nguyen interviews Curtis Knox of Lucigen on October 14, 2013. Mr. Knox will be a speaker during the Engineering Genes, Vectors, Constructs and Clones conference at PepTalk 2014, January 13-17 in Palm Springs, CA. Topics include the challenges and advantages of endotoxin reduction in recombinant protein expression processes for drug discovery R&D, high-throughput cloning and expression of target proteins, large insert metagenomic libraries from soil microbes and more.

Kip Harry interviews Dr. David Smith from the Mayo Clinic, and Dr. Melanie Lehman from Queensland University of Technology for the upcoming RNA-Seq and Transcriptome Analysis meeting, 5-6 December in Lisbon, Portugal. Discussion points during the interview include: • The advantages of using RNA-Seq for expression analysis over microarrays • The impact of RNA-Seq on research and recent advances in the applications of this technology • Ways in which RNA-Seq is being utilized clinically • Current challenges/limitations with RNA-Seq

An-Dinh Nguyen interviews Niklas Blomberg of ELIXIR on 7 October 2013. Dr. Blomberg will be a keynote speaker during the High-Scale Computing conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal. Topics include: • Bioinformatics for Managing Large Data Volumes • Sustainable IT Infrastructures for Life Science Research and Clinical Practice • Advances in IT Infrastructures for Genomic Data Management and Analysis • ELIXIR’s Mission, Considerations and Challenges

An-Dinh Nguyen interviews Wolfgang Gentzsch of The UberCloud HPC Experiment on 4 October 2013. Dr. Gentzsch will be speaking during the High-Scale Computing conference at the Clinical Genomics & Informatics Europe Conference & Expo on 4-6 December, in Lisbon, Portugal. Topics include: • Cloud Computing Services for R&D Scientists and Engineers via UberCloud • Progress in Cloud Computing and Storage for Genomic Research and Clinical Practice • Challenges: Security, Data Management, Software License Restrictions • EUDAT’s Collaborative Data Infrastructure

Terry Robins, Consultant, Former, Global Director, Scientific Affairs, Quest Diagnostics will be speaking at the Sample and Biospecimen Management in Clinical Trials Conference at the SCOPE Event in Miami Feb. 4-5, 2014. In this podcast he highlights some of the key points of his talk and gives an overview of the field.

Carl Wittwer discusses how PCR technologies have changed since the early 90s, how PCR stacks up against competing technologies like NGS, and gives a sneak peek into how PCR amplification can now be done in under 60 seconds - a technology he will discuss at the upcoming PCR for Molecular Medicine conference

Kip Harry interviews Gholson Lyon of the Cold Spring Harbor Laboratory on September 13, 2013. Dr. Lyon will be speaking during the Clinical Exome Sequencing conference at the Clinical Genomics & Informatics Europe Conference & Expo on December 4-6, in Lisbon, Portugal. Topics include: • Biology and Targeting of Cancer through Exome Sequencing • Technical Steps for Exome Sequencing • Analyzing Exome Data • Implementing Exome Sequencing in a Clinical Lab • Comparing and Contrasting Exome vs. Whole Genome Sequencing • Exome Sequencing Survey of Cancers • Standardizing Library Prep and Intra-Patient Genomic Heterogeneity • Exome Sequencing for Candidate Gene Discovery with Clinical Samples

An-Dinh Nguyen interviews Sherilyn Sawyer of BWH/Harvard Cohorts Biorepository, Brigham and Women’s Hospital on September 10, 2013. Dr. Sawyer will be speaking during the Biospecimens and Translational Science session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics include the evolution of biospecimen collection and usage, biouser needs, future challenges and opportunities.

An-Dinh Nguyen interviews Brian Chadwick of LookLeft Group LLC on September 10, 2013. Mr. Chadwick will be speaking during the Business of Running a Biobank session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics include regulatory compliance challenges of biospecimen management, software solutions, commercial vs. nonprofit biobanks, patient rights and more.

An-Dinh Nguyen interviews Allison Hubel of the Biopreservation Core Resource at the University of Minnesota on September 5, 2013. Dr. Hubel will be speaking during the Science of Supplying High-Quality Specimens session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics cover biobanking’s rising prominence, biospecimen collection and storage challenges, microfluidics applications for biopreservation and more.

An-Dinh Nguyen interviews Karen J.L. Burg of Clemson University on September 5, 2013. Dr. Burg will be a keynote speaker during the Engineering Functional 3-D Tissue Models meeting at the FAST Congress, October 28-30, in Cambridge, MA. Topics include the future evolution of 3-D tissue engineering, its multidisciplinary aspects, cell adhesion and interactions with biomaterials and clinical needs.

An-Dinh Nguyen interviews Jonathan Garlick of Tufts University on September 4, 2013. Dr. Garlick will be speaking during the Engineering Functional 3-D Tissue Models meeting at the FAST Congress, October 28-30, in Cambridge, MA. Topics cover a historical overview of engineering 3-D tissue models, their broad applicability, experimental methods for developing them and ensuring their utility, technological challenges and more.

An-Dinh Nguyen interviews John March of Cornell University on September 4, 2013. Dr. March will be speaking during the Engineering Functional 3-D Tissue Models meeting at the FAST Congress, October 28-30, in Cambridge, MA. Topics include using a 3-D cell culture system to study microorganisms of the gastrointestinal tract, using 3-D models to investigate signaling interactions, challenges in the lab and more.